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The human face holds 47 muscles that are responsible for facial expression [1]. Para-
lysis of facial muscles impairs facial expression, which causes significant physical, 
psychological and social distress. 
Facial paralysis has different etiologies which are of congenital or of acquired nature. 
If an acquired facial paralysis is caused by for instance a trauma or idiopathic, the 
paralysis might be either self-limiting or reversible through surgery. However, if the 
paralysis persists for more than 18 months or has a congenital or degenerative cause, 
the paralysis is irreversible. For these patients with longstanding facial paralysis, 
reconstructive surgery, including static or dynamic reconstructions and additional 
intensive conservative, non-surgical therapies are warranted. Currently, autologous 
free flap transplantation offers the best chance to reconstruct a spontaneous smile [2,3] 
or synchronous eye closure [4]. However, downsides of current free flap reconstruc-
tion are that only one or two of the missing muscles can be replaced, and a comple-
tely symmetrical spontaneous smile or eye closure is seldom obtained. Besides, there 
might be undue swelling of the cheek or eyelids and patients are often hindered by 
the autostatic syndrome, a situation in which the muscle that elevates the corner of 
mouth during smiling also contracts when the patient attempts to wrinkle the lips [5], 
such as in kissing. Despite advancing knowledge and improved surgical techniques, 
these conventional treatment strategies improve the functionality of one or two facial 
muscles only partly, while genuine regeneration of the muscles and movement is not 
achieved [6,7]. 
Innovative strategies based on regenerative medicine, in particular tissue engineering 
of skeletal muscle, will yield new treatment modalities for patients with longstanding 
facial paralysis. Engineered muscle tissue can be customized to the individual patient. 
Therefore, it can restore facial expression. Thus, it can improve physical and psycho-
logical symptoms.
In tissue engineering, basically tissues are reconstructed using cells and scaffolds. 
Frequently, stem cells, i.e. progenitor cells are used, because these harbor a high dif-
ferentiation capacity. A major challenge in tissue engineering is to dissect and master 
the regulatory mechanisms that govern cellular differentiation. As a progenitor cell 
for tissue engineering skeletal muscle, satellite cells seem ideal because they have 
the capacity to differentiate into skeletal muscle. Satellite cells are a cell popula-
tion present in skeletal muscle. They play a critical role in postnatal skeletal muscle 
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homeostasis, growth, repair and regeneration. As first shown by electron microscopy, 
satellite cells are mononucleated cells located between the sarcolemma of a muscle 
fiber and the basal lamina that surrounds that fiber [8]. This anatomical compartment 
serves as an instructive environment, i.e. a niche, in which satellite cells remain in a 
quiescent state or can be activated to divide and differentiate towards myoblasts and 
fuse into myotubes in response to stimuli associated with muscle growth, damage and 
repair. This makes satellite cells ideal for tissue engineering skeletal muscle.
Tissue engineering is partly an in vitro process; therefore, the satellite cell niche needs 
to be recreated to support satellite cells and facilitate activation and differentiation. 
Hence, an instructive scaffold is necessary as a carrier to provide structural support 
and participate in the regulation of cellular function. Then, for survival in vivo, tissue 
engineered skeletal muscle requires adequate vascularisation for efficient transport of 
oxygen, carbon dioxide, nutrients and waste products. And finally, innervation should 
be established. Facial muscle repair may be feasible by tissue engineering because 
these muscles are relatively small and thin, and are required to produce relative limi-
ted forces compared to most other skeletal muscles. For innervations, i.e. to replace 
the lost nerve, most patients still have a healthy facial nerve on the contra-lateral facial 
side. In addition, there are otherwise suitable options for innervation from other cra-
nial nerves such as the hypoglossal and masseteric nerve.
OUTLINE OF THIS THESIS
The main objective of this thesis is to improve tissue engineering of human skeletal 
muscle by providing new fundamental insights and methods. Therefore, an extensive 
overview of the state of play in the field of tissue engineering of skeletal muscle is 
given in chapter 2. We discuss characteristics of facial muscles and the prerequisites 
for tissue engineering of skeletal muscle including progenitor cells, scaffolds, and 
current strategies for myogenesis, vascularisation or innervation. 
In this thesis, the focus is on dissecting regulatory mechanisms in human myogenic 
satellite cells during the initial stages of myogenesis. And furthermore on the assess-
ment of muscle maturation of an engineered muscle construct in vivo.
In order to engineer human muscle tissue, human satellite cells need to proliferate 
in vitro to obtain sufficient cell numbers and further differentiate to form muscle tis-
sue. Fundamental knowledge of the processes of proliferation and differentiation of 




opportunities to alter or modify satellite cell differentiation during muscle tissue 
engineering. Thereby, we would be able to customize muscle tissue to the individual 
patients needs.
Besides the ‘traditional’ regulation of myogenesis by transcription factors, epigenetic 
regulators such as microRNAs have gained increased interest. MicroRNAs are small, 
non-coding RNAs, 20-22 nucleotides in length, involved in post-transcriptional gene 
regulation through inhibition of protein translation or enhancing messenger RNA 
degradation [9]. In chapter 3 we discuss whether and if so, which microRNAs have 
a regulatory function in the differentiation of human satellite cells. By modifying 
human satellite cell differentiation, the engineering of muscle tissue could be impro-
ved. Therefore, in chapter 4, the application of this regulating function of microR-
NAs in tissue engineering skeletal muscle is investigated at 2D and 3D level. 
In tissue engineering, the ultimate goal is in vivo application of engineered muscle tis-
sue. At that point, human satellite cells will encounter hypoxic environments. In nor-
mal human muscle tissue, satellite cells respond to hypoxic muscle damage with acti-
vation, proliferation, differentiation, and maturation, while maintaining their reserve 
pool of satellite cells ref. Hypoxic environments might therefore even be beneficial in 
culturing satellite cells and further differentiation in vivo. Hence, a better understan-
ding of the response of human satellite cells to changes in oxygen level is required. 
This is investigated and discussed in chapter 5.
As a proof of concept, in vivo maturation of an in vitro engineering 3D muscle con-
struct is investigated in chapter 6. Although facial muscles are thinner than most 
other skeletal muscles, their thickness needs to exceed 0.2 mm to be functional, i.e. 
generate sufficient force to move facial skin. Vascularisation is important for the sur-
vival of satellite cells and myofibers after implantation. Therefore, we also investiga-
ted whether human endothelial cells are beneficial for the vascularisation of a tissue 
engineered muscle construct in vivo.
Finally, chapter 7 discusses the main and important fundamental findings of this the-
sis and provides future perspectives of tissue engineering human skeletal muscle for 
the benefit of patients with longstanding facial paralysis.
CURRENT OPPERTUNITIES AND 
CHALLENGES IN SKELETAL 
MUSCLE TISSUE ENGINEERING
Merel Koning, Martin C. Harmsen, 
Marja J.A. van Luyn, Paul M.N. Werker






The purpose of this article is to give a concise review of the current state of art in tis-
sue engineering (TE) of skeletal muscle, the opportunities and challenges for future 
clinical applicability.
The endogenous progenitor cells of skeletal muscle i.e. satellite cells, show a high 
proneness to muscular differentiation, in particular exhibiting the same characteristics 
and function as its donor muscle. This suggests that it is important to use an appropri-
ate progenitor cell, especially in TE facial muscles, which have a exceptional anato-
mical- and fibercomposition compared to other skeletal muscle. 
Muscle TE requires an instructive scaffold for structural support and to regulate the 
proliferation and differentiation of muscle progenitor cells. Current literature suggests 
that optimal scaffolding could comprise of a fibrin gels and cultured monolayers of 
muscle satellite cells obtained through the cell sheet technique.
Tissue engineered muscle constructs require an adequate connection to the vascular 
system for efficient transport of oxygen, carbon dioxide, nutrients and waste products. 
Finally, functional and clinically applicable muscle constructs depend on adequate 
neuromuscular junctions with neural cells. To reach this, it seems important to apply 
optimal electrical, chemotropic and mechanical stimulation during engineering, and 
discover other factors that influence its formation. Thus, in addition to approaches for 
myogenesis, we will discuss current status of strategies for angiogenesis and neuroge-




Paralysis of facial muscles, which provide facial expression, may lead to great phy-
sical and social distress for the patient. Despite advancing knowledge and improved 
surgical techniques, outcome of current treatment remains at best suboptimal [10-12].
Tissue engineering (TE) may offer an alternative future solution. In general, TE 
employs progenitor cells and scaffolds that together generate the appropriate environ-
ment to functionally repair, replace or regenerate lost or damaged tissue. Engineered 
muscle tissue may be customized to the individual patient and offers an opportunity 
for patients to improve physical and psychological symptoms and reach near to nor-
mal mimical function.
Nevertheless, muscle TE has limitations and challenges. Specific myogenic progeni-
tor cells, scaffolds to support growth and differentiation of progenitor cells, and bio-
active factors are required. Functional skeletal muscle requires parallel alignment of 
muscle fibers with myosin/actin filaments, and acetylcholine receptors to create direct 
forces. Besides, the tissue engineered muscle must be vascularised and innervated for 
future clinical application. Furthermore, the scaffold must be biocompatible [13,14].
The purpose of this article is to give a concise review of the current state of art in TE 
of skeletal muscle and its significance for future clinical use.
FACIAL MUSCLE CHARACTERISTICS
The human face holds 23 paired facial muscles and one unpaired, the orbicularis oris 
muscle [15]. Unlike other skeletal muscles which are spanned out between bones, 
facial muscles attach at least on one side to skin. Contraction of the facial muscles 
gives facial expression by moving the skin. 
Each facial muscle is made up out of 75 to 150 muscle fibers [16]. They are arranged 
into parallel bundles, which run from origin to insertion [17].
In general, two types of fiber can be distinguished: Type I, or slow twitch muscle 
fibers that produce large amounts of energy at a slow pace, which allows them to 
work for a long time without getting exhausted; Type II:, or fast twitch muscle fibers 
produce small amounts of energy very quickly. This enables rapid movements, but 
causing great fatigability. Type II fibers are further subdivided in type IIA and type 
IIB (Table 1).  
2
15
CURRENT OPPERTUNITIES AND CHALLENGES
Muscles are made up of a mixture of type I and type II muscle fibers. Muscles con-
sisting mainly of type I fibers are red and well perfused, because they contain many 
capillaries. They depend on a rich supply of oxygenated blood. Type II fibers are 
primarily dependent on anaerobic metabolism, no rich blood supply is needed and 
consequently muscles that consist mainly of type II fibers are more white colored [18].
The zygomaticus minor has the largest proportion type II fiber (89.1 %) reported in 
human skeletal muscle. Besides, the zygomaticus major and minor muscles have a 
marked predominance of a subtype II fiber, intermediate between type IIA and type 
IIB. The presence of these oxidative type IIAB fibers indicates a high resistance to 
fatigue. Besides, facial muscles lack a firm insertion, static contraction and subse-
quent development of high tension is prevented. Therefore, blood circulation is not 
obstructed, and fatigability is further postponed [19]. 
Table 1. Characteristics of skeletal muscle fiber type.
Type I Type IIA Type IIX Type IIB 
Contraction time Slow Moderately 
Fast 
Fast Very fast 
Size of motor neuron Small Medium Large Very large 
Resistance to fatigue High Fairly high Intermediate Low 
Maximum duration 
of use 
Hours <30 minutes <5 minutes <1 minute 
Force production Low Medium High Very high 
Capillary density High Intermediate Low Low 
Oxidative capacity High High Intermediate Low 
PROGENITOR CELLS
An important prerequisite for engineering skeletal muscle is using a suitable, autolo-
gous progenitor cell. This cell should be cultured, expanded and capable to differenti-
ate into the cell types of muscle tissue. 
Mesenchymal stem cells from several different sources harbor myogenic potency. 
16
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Bone marrow-derived mesenchymal stem cells (MSCs) are able to differentiate into 
myoblasts with a high efficiency [20]. Myoblasts fuse with each other to form myo-
tubes, which differentiate to muscle fibers. MSCs have a high proliferation capacity 
and are capable of self-renewal. This renders them suitable as progenitor cells for 
skeletal muscle TE. Furthermore, they can be transplanted autologous and expanded 
efficiently in vitro to reach therapeutic scale [20,21]. Expansion of harvested cells 
is necessary in TE to create sufficient volume of skeletal muscle in order to deliver 
enough force to be functional in future clinical application. However, myogenic line-
age induction in MSCs is an additional differentiation step. Furthermore, harvesting 
MSCs from bone marrow is a relatively invasive procedure for the patient.
Skeletal muscles on the other hand, harbor their own endogenous organ-specific mes-
enchymal stem cells, i.e. satellite cells. These are, unlike MSCs, already prone to 
myogenic differentiation, and therefore seem more suitable for skeletal muscle TE. 
Satellite cells are sequestered between the sarcolemma and mature muscle fibers and 
normally do not proliferate. In response to specific local challenges such as muscle 
damage, myogenic satellite cells start to proliferate. They migrate through the basal 
lamina sheets to areas of injury, differentiate into myoblasts and fuse with pre-exis-
ting, damaged fibers or with each other and ultimately differentiate to muscle fibers. 
Remarkably, if satellite cells fail to fuse they dedifferentiate back to quiescent satellite 
cells [22]. Myogenic satellite cells can be harvested from muscle tissue, which is easy 
accessible, and propagated in vitro.
Unfortunately, the differentiation processes towards myofibers still appear difficult to 
induce and control in vitro. Therefore, frequently cell lines are used such as C2C12, 
which are satellite cells of C3H mice [23-29]. Also, satellite cells harvested from 
the soleus muscle of rats are used for TE of muscle tissue [28,30-36,36,37]. Other 
muscles harvested for TE research include the latissimus dorsi and rectus femoris of 
rats [38], flexor digitorum brevis of rats [39], tibialis anterior of rats [23,28,36,36], 
the extensor digitorum longus of mice [23], the human masseter [40-44] and brachi-
oradialis [45], and the iliofibularis from female Xenopus laevis frogs [46] (Table 2).
Even in vitro, the predetermination of satellite cells is preserved. In other words, the 
source of muscle fiber type predisposes satellite cells differentiation: Huang et al. 
showed that characteristics of muscle fibers tissue engineered of soleus muscle satel-
lite cells are different from those obtained of tibialis anterior muscle satellite cells. 
For example, the contraction/relaxation time is slower in muscle constructs derived 
of satellite cells of soleus muscle compared to muscle constructs derived of satellite 
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Table 2. Sources of progenitor cells.





Bone marrow Mesenchymal stem 
cell
Lewis MP. Human Masseter muscle Satellite cell
Shah R. 
Sinanan AC. 
Stern-Straeter J.   
Alessandri G. Human Brachioradialis muscle Satellite cell






Boontheekul T.  








Boontheekul T. Rat Tibialis anterior muscle Satellite cell
Huang YC.  
Dennis RG. 
Boontheekul T.  
Kamelger FS. Rat Latissimus dorsi muscle Satellite cell 
Kamelger FS. Rat Rectus femoralis muscle Satellite cell 
De Coppi P. Rat Flexor digitorum brevis 
muscle 
Satellite cell 
Dennis RG. Mice Extensor digitorum 
longus muscle 
Satellite cell 
Jaspers RT. Frog Iliofibularis muscle Satellite cell 
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cells of tibialis anterior muscle [47]. This suggests a strong imprinting of myogenic 
satellite cells. 
McLoon et al. suggested that facial muscles contain satellite cells with unique abili-
ties, amongst which a higher quantity and resistance to apoptosis, which renders them 
more favorable for TE than other skeletal muscle derived satellite cells [48]. 
A difficulty lies in culturing differentiated skeletal muscle. Sinanan et al. investiga-
ted an approach to purify the population of myogenic satellite cells through CD56pos, 
which is a cell adhesion molecule (NCAM) expressed in proliferating myoblasts [49]. 
Though the resulting cell population has a higher percentage of desmin [41], which is 
an intermediate filament protein, force production of this population was significantly 
lower in comparison to the mixed and CD56neg cell populations [43]. 
Previously mentioned MSCs harbor a side population of CD31neg CD45neg mesen-
chymal stem cells that reside in bone marrow [50,51], but also skeletal muscle itself 
[52-55]. A co-culture of myogenic satellite cells and this side population of CD31neg 
CD45neg mesenchymal stem cells is another approach in stimulating proliferation and 
differentiation of myogenic satellite cells.
However, hurdles still remain concerning differentiation towards functional skeletal 
muscle before TE is clinically applicable in patients with facial paralysis.
The proneness of satellite cells for myogenic differentiation, the strong imprinting 
and the unique characteristics of facial muscles suggest that it is important for the 
functional outcome in TE of facial muscles to use appropriate progenitor cells, such 
as satellite cells derived of facial muscle.
SCAFFOLDS
In vivo, the extracellular matrix (ECM) of muscles provides muscle fibers with the 
architecture to support development and function. Thus, TE of functional skeletal 
muscle requires a scaffold to mimic the ECM, to support proliferation and differenti-
ation of progenitor cells [38]. 
Different types of scaffolds have been developed with regard to their physiochemical 
features and compositions, as well as their biological characteristics (Fig. 1). 
Although several studies have addressed the development of an optimal non-biode-
gradable scaffold, like phosphate based glass [44], biodegradable scaffolds are prefer-
red, because upon degradation, remodeling to the natural muscular ECM can occur. 
2
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Both synthetic and natural scaffolds have been developed. Synthetic biodegradable 
three dimensional (3D) scaffolds that hold promise for muscle TE are polymers made 
of polylactic-co-glycolic acid (PGA) fiber mesh sheets [56]. These have been found 
to provide both appropriate rigidity and connection. Aligned nanoscale and micros-
cale topographic features of a polymer scaffold both cause alignment of myoblasts 
and cytoskeletal proteins, and promote myotube assembly along the nanofibers and 
microgrooves to mimic the myotube organization in muscle fibers. This alignment is 
an important requirement of functional skeletal muscle. Furthermore, they enhance 
myotube striation, restrict cell spreading and finally suppress myoblast proliferation 
during differentiation and cell fusion. Nanoscale features are more efficient in promo-
ting the assembly of longer myotubes than microscale features [27].  Parallel align-
ment can also be induced by applying mechanical or magnetic strain: muscle fibers 
reorganize along the line of force [29,57] and through static magnetic fields [58].
Also in a natural biodegradable 3D scaffold, like collagen, aligned topographic fea-
tures cause alignment of myoblasts and cytoskeletal proteins [59,60]. A natural bio-
degradable 3D scaffold can also be made of acellular muscle ECM [24]. A drawback 
of this type of scaffold is its extreme fragility and associated difficulties of hand-
ling. Another natural biodegradable 3D scaffold can be created by using fibrin. Satel-
lite cells are mixed with a growth medium, fibrin and thrombin to create a fibrin gel 
[29,31,32,37,61]. Muscle progenitor cells produce their own ECM proteins and over 
3 to 4 weeks degrade and replace the original fibrin matrix [36], which is important 
Figure 1. Different designs for scaffolds currently used in muscle TE.
20
CHAPTER 2
because myoblasts proliferate more extensively in fast degrading gels [28]. This pro-
cess is much similar to wound healing i.e. repair, in which fibrin forms a temporary 
scaffold to serve tissue regeneration. Upon completion of wound healing i.e. repair, 
the fibrin has been replaced by the physiological ECM. Fibrin has the additional 
advantage that it binds growth factors, such as fibroblast growth factor (FGF-2), vas-
cular endothelial growth factor (VEGF) and indirectly insulin growth factor (IGF-1), 
which all augment myogenesis. Myoblasts seeded on fibrin gels have been shown to 
differentiate into contracting muscle fibers and demonstrate a normal length-tension 
and force-frequency relationship [36].
In vitro seeding of myogenic progenitor cells on a scaffold has been found to enhance 
differentiation into muscle fibers after implantation in vivo and results in ingrowth of 
a nourishing capillary network. This might be part of the foreign body reaction that 
occurs after implantation of a skeletal muscle construct in vivo [38,62,63].
An alternative technique which does not require a 3D scaffold is cell sheet technology 
[64-70]. Although originally developed for myocardial TE purposes [70], the techni-
que has found its way to other fields of TE, like liver [69] and cornea [65], and is pro-
mising for engineering facial muscles. It exercises the use of temperature responsive 
2D scaffolds made out of polymer: poly(N-isoproplyacrylamide). By increasing the 
temperature, the cell layer becomes afloat, which allows non-invasive harvesting, i.e. 
without the use of enzymes such as trypsin. By means of a stamp, the cultured cells 
can be processed as intact sheets, along with their deposited ECM. Out of these cell 
sheets, 3D constructs can be created by layering these cell sheets (Fig. 2). However, 
the number of cell sheet layers is limited because developing myoblasts are unable to 
proliferate and differentiate greater than approximately 150 μm from a nutrient source 
[30]. 
The mentioned scaffolds all have their own advantages. Parallel alignment can be 
reached through aligned topographic features, fibrin promotes cell proliferation, the 
cell sheet technique offers an excellent architecture of monolayers. Combined, they 
would seem to form the ideal scaffold for skeletal muscle TE (Fig. 3).
INNERVATION
One of the key features for innervation of a muscle construct is formation of a motor 
end plate, the neuromuscular junction between the motorneuron and every individual 
2
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Figure 2. Concept of in vitro TE of skeletal muscle with three different types of scaffolds.
Figure 3. In culturing progenitor 
cells for skeletal muscle TE, an 
ideal scaffold can be developed by 
combining the advantages of alig-
ned topographic features, fibrin and 
the cell sheet technique. Vasculari-
zed tissue may develop by layering 
cell sheets on a vascular bed and 
functional muscle tissue might be 
constructed with appropriate stimuli 




muscle fiber of the construct. 
It is important to understand the influence on, and the effect of chemotropic, electrical 
and mechanical stimulation on cultured myoblasts with respect to their proliferation 
and differentiation.
During in vivo myogenesis acetylcholine receptors (AChR) are expressed randomly 
along the surface of myoblasts. Stimulation induces the accumulation of AChR in the 
plasma membrane of developing muscle fibers [35]. Whenever a motor nerve comes 
in the vicinity of such an AChR-spot, a motor end plate may develop. Continuous 
communication between the muscle fibers and the nerve is necessary in maintaining 
the neuromuscular junction, because these junctions disappear upon loss of commu-
nication [71].
In co-cultures of myotubes and neural cells neuromuscular-like junctions appear to 
form spontaneously. On muscle cells AChR are accumulated and are surrounded by 
neural extensions that harbor neurofilaments. These nerve-muscle constructs show 
spontaneous contractions and can also be stimulated [72]. Larkin et al. showed in 
vitro that stimulated nerve-muscle constructs had better contractility characteristics 
than muscle-only constructs: muscle-only constructs, produced a twitch force of 40 
µN, and a tetanic force of 95 µN, while stimulated nerve-muscle constructs produced 
a twitch force of 100 µN, and a tetanic force of 200 µN [35]. Dhawan et al. showed 
that in vivo neurotization of skeletal muscle constructs led to better contractibility ex 
vivo compared to the non-neurotizated skeletal muscle constructs [73]. This indicated 
that skeletal muscle constructs display a greater maturity, and thereby a higher force 
production in the presence of neural cells and neuromuscular junctions.
The most important contraction proteins of muscle fibers are desmin and myosin 
heavy chain (MHC). Besides, myogenic regulator factors (MRFs), such as MyoD and 
myogenin, regulate expression of AChR as part of the motor endplate development. It 
has been found that the expression of desmin, MHC and MRFs can be strongly influ-
enced by chronic electrical stimulation, which imitates in vivo neuronal activity during 
myogenesis in vitro [74,75]. Huang et al. used this concept on muscle fiber constructs 
from soleus and tibialis anterior muscle satellite cells and found an increase in force 
production of 61–80 % in soleus muscle constructs, without an increase in total MHC 
[47]. They hypothesized that the increase in force production is caused by reorganiza-
tion of sarcomeres within muscle fibers promoted by chronic low-frequency electrical 
stimulation, and/or a change in matrix produced by muscle cells, which allowed for 
2
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better transmission of force to the anchor materials, specifically designed to serve as 
artificial tendons. Unfortunately, this protocol was not found to be universally effec-
tive, since it did not show this effect in the tibialis anterior muscle constructs. 
This once again emphasizes that characteristics of satellite cells used to generate mus-
cle constructs determine, amongst others, the contractile force of a muscle construct.
Although proof-of-principle experiments showed that electrical stimulation was 
essential for the formation and maintenance of functional signaling between motor 
nerve and muscle fiber, other experiments showed that, depending on the nature of 
this electrical stimulation, also opposite effects can be achieved [71,75]. 
When contractions exceeded 800 a day, loss of muscle mass and force production was 
found within 24 hours. In vivo this is within the normal range for fast twitch muscle, 
but apparently in this culture this is inappropriate [47].
It is a fundamental feature of skeletal muscle in vivo as well as in vitro that optimal 
force production is a function of stimulation voltage and frequency. Therefore, elec-
trical stimulation needs to be further optimized in terms of frequency, pulse width, 
and train duration to minimize tissue damage and maximize beneficial phenotypic 
alterations.
As said before, the formation of the neuromuscular junction is also influenced by 
chemotropic stimulation. Myoblasts appear to undergo dramatic phenotypic changes 
upon prolonged culturing and passaging. This was found to be most prominent for 
the expression of MRFs such as MyoD and myogenin, and thus for AChR expres-
sion. Myoblasts that underwent low passage have a higher expression level of MyoD, 
myogenin and AChR compared to myoblasts that underwent high passage. It also 
has a diminishing effect on the force production [32]. This indicates that frequent 
passaging of cells delays synaptic signaling between the motor nerve ending and the 
muscle fibers. 
In conclusion, for developing of a fully functional neuromuscular junction with neural 
cells, it seems important to apply the optimal electrical, chemotropic and mechanical 
stimulation and discover other factors that influence its formation.
VASCULARISATION
In contrast to the limited research into innervating tissue engineered skeletal muscle 
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constructs, there has been extensive research into vascularisation of these constructs. 
This is very important since a major limiting factor in creating skeletal muscle via TE 
is that myoblasts are unable to proliferate and differentiate greater than 150 μm from a 
nutrient source and oxygen supply [30]. Obviously, most muscles are thicker than 300 
μm. Thus, every muscle construct must be connected to a vascular system for efficient 
transport of oxygen, carbon dioxide and nutrients and waste products. 
Different options have been studied. First, implantation in vivo of muscle constructs 
gives the foreign body reaction that results in ingrowth of a supportive capillary net-
work that subsequently promotes and maintains viability [61,62,76,77]. Still, to engi-
neer thicker, functional tissue, an integrated vascular system is required.
The second option includes fibrin gel fixed around a preformed ectopic arteriovenous 
loop in rats [37]. If primary expanded myoblasts are injected into this prevascularised 
fibrin gel, vascularised muscle tissue is expected to develop. However, Bach et al. 
showed that, although cells survived and kept their myogenic phenotype, muscle fiber 
formation was not reached yet. Differentiation of myoblasts failed in these experi-
ments [37], opposite to the experiments of Huang et al., which showed that fibrin gel 
as a scaffold promotes proliferation and differentiation of myoblasts [36]. It might be 
that potent stimuli, like chemotropic, electrical and mechanical stimulation, which 
are necessary for differentiation of myoblasts into muscle fibers, were lacking in the 
experiments of Bach et al.
Third, Borschel et al. implanted engineered skeletal muscle constructs around femoral 
vessels in rats. This led to the formation of vascularised skeletal muscle tissue which, 
when electrically stimulated, produced a longitudinal specific force of 35.4 ± 62.2 N/
m2 [34]. 
Fourth, Levenberg et al. developed so called prevascularised skeletal muscle con-
structs from cultures of myoblasts, endothelial cells and embryonic fibroblasts, in 
which enhancement of the vascular network was perceived. This appears of major 
interest because these in vitro prevascularised muscle constructs showed less apopto-
sis of cells after implantation in vivo, than muscle constructs that were not prevascu-
larised. Reduction of apoptosis is correlated to vessels in muscle constructs that form 
anastomoses with the host vasculature [25]. Further research is needed to establish 
whether this model is applicable in humans, the use of a xenogenic culture system 
(human and animal) in combination with embryonic cells is more than questionable, 
since embryonic tissue might give rise to malignant proliferation and implantation of 
animal tissue gives rise to an immunological response.
2
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CURRENT OPPERTUNITIES AND CHALLENGES
The cell sheet method mentioned earlier also holds promise to the concerted vascula-
risation of muscle constructs. By implanting the maximum of cell sheets over a vas-
cular system, neovascularisation occurs in vivo [78]. If sufficient neovascularisation 
occurs, a new layer of cell sheets can be applied on top of the previous, where after 
neovascularisation of the new layer of cell sheets takes place. Through this kind of 
polysurgery, which applies the use of repeated transplantations after neovascularisa-
tion, thick muscle tissue with connectable vessels may be produced [78-80,80,81]. 
This technique has not yet been used for engineering skeletal muscle, and current 
method is not practical in a human situation. Combining the cell sheet technique with 
a fibrin coating and aligned topographical features, with a co-culture of myogenic 
satellite cells and endothelial progenitor cells, this technique can be made applicable 
in a human situation.
CONCLUDING REMARKS AND PERSPECTIVE
Human myogenic satellite cells are at present the first choice for skeletal muscle TE 
purposes. Characteristics of satellite cells used for TE have a direct effect on charac-
teristics and contractility of resulting muscle tissue. Further research is required to 
determine whether satellite cells from facial muscles are applicable to tissue engineer 
new facial tissue and whether a combination with other mesenchymal stem cells is 
preferred in developing specific characteristics necessary for clinical application in 
patients with facial paralysis.
A scaffold should promote proliferation of satellite cells, differentiation and parallel 
alignment. Aligned topographic features, fibrin and the cell sheet technique all have 
their own advantages, which combined would seem to form an ideal scaffold for engi-
neering functional skeletal muscle.
It seems possible to create a functional neuromuscular junction through co-culture of 
myotubes and neural tissue, or by means of electrical stimulation. However, innerva-
ting the muscle construct remains a major hurdle for clinical applicability of skeletal 
muscle created via TE.
Vascularisation of the muscle construct is essential to accomplish volume neces-
sary for the construct to be functional in clinical application. This could be reached 
through in vivo implantation of a preformed muscle construct around a vascular pedi-
cle, through implantation of myoblasts in a prevascularised fibrin gel, or through the 
cell sheet method. These options are currently not suitable for human application and 
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an in vitro model seems to have the most potential. We anticipate that by combining 
different scaffold techniques and co-culturing different cell types, further process can 
be made in engineering functional skeletal muscle.
Together these new technologies provide a novel insight in an alternative and impro-
ved method for reconstructive surgery in patients with facial paralysis.
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During myogenesis, human satellite cells differentiate and form multinucleated myo-
tubes, while a fraction of the human satellite cells enter quiescence. These quiescent 
satellite cells are able to activate, proliferate and contribute to muscle regeneration. 
Post-transcriptional regulation of myogenesis occurs through specific myogenic 
microRNAs, also known as myomiRs. Although many microRNAs are involved in 
myotube formation, little is known on the involvement of microRNAs in satellite cells 
entering quiescence. This current study aims to investigate microRNA involvement 
during differentiation of human satellite cells, specifically proliferating satellite cells 
entering quiescence.
For this, clonally expanded human satellite cells were differentiated for 5 days, after 
which myotubes and quiescent satellite cells were separated through FACS sorting. 
Next, a microRNA microarray comparison of proliferating satellite cells, myotubes 
and quiescent satellite cells was performed and verified through qRT-PCR.
We show that during human satellite cell differentiation, microRNAs are globally 
downregulated in quiescent satellite cells compared to proliferating satellite cells, 
in particular microRNA-106b, microRNA-25, microRNA-29c and microRNA-
320c. Furthermore, we show that during myogenesis microRNA-1, microRNA-133, 
microRNA-206 and microRNA-486 are involved in myotube formation rather than 
satellite cells entering quiescence. Finally, we show an overall decrease in total mRNA 
in quiescent satellite cells, and an indication that RNaseL regulation plays a role in 
promoting and maintaining quiescence. Given the importance of quiescent satellite 
cells in skeletal muscle development and regenerative medicine, it is imperative to 
distinguish between myotubes and quiescent satellite cells when investigating skeletal 
muscle development. Especially in microRNA studies, since we show that microR-





Muscle tissue has its own endogenous repair and maintenance system which is based 
on myogenic progenitor cells, i.e. satellite cells. In vivo, satellite cells are activated 
upon tissue damage, they proliferate and differentiate, fuse with existing myofibers 
and thereby contribute to the regeneration of damaged muscle [82-86]. During diffe-
rentiation in vitro, part of the human satellite cells form multinucleated myotubes, and 
the other part enters quiescence [87,88]. While myotubes are terminally differentiated, 
these quiescent satellite cells, also called reserve cells [89], are still able to activate, 
proliferate and differentiate to form myotubes and contribute to muscle regeneration 
and repair. The ability to adapt to two distinct cell fates, i.e. towards myotube forma-
tion or quiescence in the same microenvironment is unique for satellite cells [90,91]. 
The myogenic differentiation process is transcriptionally regulated through factors 
such as Pax7 and the myogenic regulator factors MyoD and Myogenin. While post-
transcriptional regulation further occurs through specific myogenic microRNAs, also 
known as myomiRs [92,93].
MicroRNAs are small, non-coding RNAs, 20-22 nucleotides in length, involved 
in post-transcriptional gene regulation through inhibition of protein translation or 
enhancing messenger RNA degradation. MyomiRs have an important role in skeletal 
muscle development and disease [94-99]. A major effect of microRNAs in myoge-
nesis is that they modulate proliferation as well as differentiation of satellite cells 
[9]. MicroRNA-133 promotes satellite cell proliferation through repressing the Serum 
Response Factor [100], but is not essential in skeletal muscle development [101]. 
MicroRNA-1, microRNA-206 and microRNA-486 are strongly upregulated during 
satellite cell differentiation and subsequent muscle development. They improve 
muscle differentiation by inhibiting PAX7 translation such that MYOD1 is no lon-
ger inhibited and myotube formation progresses [102-105]. Finally, other microR-
NAs that improve myotube formation are microRNA-181 that targets Hox-A11[106], 
microRNA-24 [107,108] and microRNA-27 that facilitates the start of myotube for-
mation by targeting PAX3 [109]. Also microRNA-29 improves myotube formation by 
targeting HDAC4 [110], thereby preventing muscle degeneration [111]. 
Although many microRNAs are involved in myotube formation, little is known on 
the involvement of microRNAs in satellite cells entering quiescence, which is of 
importance in skeletal muscle regeneration. This current study aims to investigate 
microRNA involvement during differentiation of human satellite cells through a 
microRNA microarray of proliferating satellite cells, myotubes and quiescent satellite 
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cells to elevate the knowledge of microRNAs during differentiation of human satel-
lite cells.
MATERIALS AND METHODS
Satellite cell isolation and culture
A muscle biopsy was obtained from a healthy female donor, undergoing blepharo-
plasty. The age of the donor was 60 years. The study protocol was approved by the 
institutional medical ethics committee, and the donor gave her informed consent. 
Satellite cells were isolated with 0.04 mg/ ml (0.16 Collagenase Wünsch units/ml) 
Liberase Blendzyme 3 (Roche Applied Science, the Netherlands) as described previ-
ously [112]. Proliferation medium consisted of Dulbecco’s Modified Eagle Medium 
(DMEM) (Invitrogen/Gibco, CA, USA), 20 % Fetal Bovine Serum (FBS; Invitrogen/
Gibco) and 1 % penicillin/streptomycin 50 μg/ml (Sigma-Aldrich, St. Louis, USA). 
Differentiation medium (DM), contained DMEM, 2 % FBS, 1 % penicillin/strepto-
mycin, 1 % Insulin-Transferrin-Selenium-A (100x) (Invitrogen) and 0.4 μg/ml dexa-
methason (Sigma-Aldrich). Medium was refreshed three times per week. Cells were 
plated at 5.0 x 103 cells/cm2 in culture flasks precoated with 1 % gelatine/PBS for 
30min. When cells reached 70 % confluence, they were enzymatically harvested 
using accutase (Invitrogen) and passaged. Passage number (Px) was defined as the xth 
sequential harvest of a subconfluent cell population. At passage 8, cells were cloned 
by sorting single cells in 96 wells plates using a MoFlow FACS. The fraction of 
human satellite cells that was able to clonally expand was 26.3 ± 4.0 %. A clone that 
uniformly expressed the satellite cell marker Pax7 and the myogenic regulator factors 
MyoD and Myogenin was selected for further experiments. 
After 5 days differentiation, we sorted mononuclear cells and myotubes by first har-
vesting the whole cellfraction using accutase (Invitrogen), then sieving the cellfrac-
tion through a 70 µm sieve. Next, we stained the flowthrough with 5 µg/ml Hoechst 
(Invitrogen) for 30 min at room temperature and finally we performed sorting by 
FACS to obtain the mononucleated fraction. Proliferating satellite cells were handled 
similarly, and myotubes were retrieved of the sieve filter.
Immunofluorescent staining 
Cells were cultured on Thermanox® coverslips, Lab-Tek chamber slides or 96 wells 




100 % confluence, cells were fixed or cultured for an additional five days in DM and 
subsequently fixed in 2 % paraformaldehyde (PFA) at room temperature for 10 min. 
A permeabilization step was performed with 0.5 % Triton X-100 (Sigma-Aldrich) in 
PBS at room temperature for 10 min. Non-specific binding-sites were blocked with 
10 % Goat serum in PBS for 30 min. Cells were incubated with the primary antibody 
in PBS and 2 % serum at room temperature for 60 min or at 4 °C overnight. The 
primary antibody consisted of either a proliferation marker, rabbit-anti-human Ki67 
(1:100) (Sanbio, Uden, the Netherlands), a satellite cell marker, mouse-anti-human 
Pax7 (1:10) (Developmental Studies Hybridoma Bank (DSHB), Iowa, USA), a myo-
genic marker, rabbit-anti-human desmin (1:100) (Novus Biological, Littleton, USA), 
a myogenic transcription factor, mouse-anti-human MyoD (1:100) (Dako, Glostrup, 
Denmark), a myogenic transcription factor, mouse-anti-human myogenin (1:100) 
(DSHB), a sarcomere component, mouse-anti-human myosin (MF20; 1:500) (DSHB) 
and mouse-anti-human RNaseL (1:100) (Abcam, Cambridge, UK). After three washes 
with 0.05 % Tween in PBS the cells were incubated with a secondary antibody-cock-
tail at room temperature for 30min. The secondary antibody-cocktail constituted of 
FITC-conjungated goat-anti-rabbit IgG (1:100) (Southern Biotech, AL, USA), Alexa 
Fluor®488 goat-anti-mouse IgM and Alexa Fluor® 555 goat-anti-mouse IgG1 or 
IgG2b (all Invitrogen) (1:300 in PBS/DAPI containing 10 % normal human serum). 
Samples were mounted in Citifluor AP1 (Agar Scientific, Essex, UK). Examination 
was performed by immunofluorescent microscopy using a Leica DMRXA microscope 
and Leica Software (Leica Microsystems, Wetzlar, Germany), and further quantifica-
tion was performed by TissueFAXS using a Zeiss AxioObserver.Z1 microscope and 
TissueQuest Cell Analysis Software (TissueGnostics, Vienna, Austria).
Gene transcript analysis
Total RNA was isolated from approximately 200,000 cells using the Rneasy Kit 
(Qiagen Inc., CA, USA), in accordance to the manufacturer’s protocol. Briefly, a cell 
lysate was made and diluted with an equal volume of ethanol (70 %). RNA was col-
lected on an RNA binding filter by centrifugation. DNA was removed by incubation 
with a DNase I solution at 37 °C for 15 min. The RNA-binding filter was washed 
twice and subsequently the RNA was eluted with 14 μl Elution Buffer. The RNA 
concentration and purity were determined by spectrophotometry (NanoDrop Techno-
logies, Wilmington, NC). For qRT-PCR analysis, total RNA was reverse transcribed 
using the First Strand cDNA synthesis kit (Fermentas UAB, Lithuania). In summary, 
1μg of total RNA was diluted in a final reaction volume of 20μl containing random 
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hexamer primer (0.5 μg), RiboLock™ Ribonuclease Inhibitor (20 U), 1 mM dNTP 
mix, and incubated at 37 °C for 1 h. The reverse transcription reaction was terminated 
by heating the mixture to 70 °C for 10 min, after which the samples were placed on 
ice. Quantitative RT-PCR analysis was performed in a final reaction volume of 10 μl, 
consisting of SYBR Green Supermix (Bio-Rad, Hercules, USA), 0.5 mM primer-mix 
(Table 1) and 5 ng cDNA. Reactions were performed at 95 °C for 15 s, 60 °C for 30 s, 
72 °C for 30 s, for 40 cycles. Analysis of the data was performed using Science Detec-
tion Software 2.2.2. To determine differences in expression, Ct-values were normali-
zed against GAPDH-expression using the ΔCt-method (ΔCt(gene) = Ct(gene) – Ct(GAPDH)). 
Relative expression levels were calculated as 2-(ΔCt). All cDNA samples were amplified 
in triplicate.









Total RNA was isolated from approximately 200,000 cells using the mirVana kit 
(Ambion), in accordance to the manufacturer’s protocol. Briefly, a cell lysate was 
made and diluted with 1.25 volumes of ethanol (100 %). RNA was collected on a 
RNA binding filter by centrifugation. The RNA concentration and purity were deter-
mined by spectrophotometry (NanoDrop Technologies, Wilmington, NC). 
Microarray analysis of proliferating satellite cells, myotubes and quiescent satellite 
cells (N = 3) was performed according to the manufacturer’s protocol (Agilent, Santa 
Clara, SA). Briefly, first strand cDNA was synthesized from 100 ng RNA, followed by 
cRNA amplification and labeling with Cy3. Samples were hybridized in a dye swap 
design at 65 °C overnight on Agilent microRNA Microarray 16.0. The following day, 
slides were washed and signals were scanned with GenePix 4000B (Agilent). Signal 
intensities from scanned images were processed and converted into normalized data 




a quality control report was generated using GeneSpring GX version 9.0 (Agilent). 
cDNA synthesis was performed using the microRNA Reverse Transcription Kit 
(Applied Biosystems). In summary, 25 ng of total RNA was diluted in a final reaction 
volume of 5 μl with 1.25 μl 6 µM microRNA specific RT-primer (Table 2) and 1.25 
μl RT-master mix, containing 1mM dNTP mix, multiscribe RT enzyme, RT Buffer, 
RNase Inhibitor and water. This was incubated at 16 °C for 30 min, 42 °C for 30 
min, 85 °C for 5 min, and subsequently mixed with 0,5 μl 10 µM microRNA specific 
qRT-primer and 0,5 μl 10 µM reverse primer (Table 2). Quantitative RT-PCR analysis 
was performed with 25 ng cDNA-primer mix and 4 μl SYBR Green Supermix (Bio-
Rad, Hercules, USA). Reactions were performed at 95 °C for 15 s, 60 °C for 60 s, 
for 45 cycles. Analysis of the data was performed using Science Detection Software 
2.2.2. To determine differences in expression, Ct-values were normalized against 
RNU6B-expression using the ΔCt-method (ΔCt(microRNA) = Ct(microRNA) – Ct(RNU6B)). Rela-
tive expression levels were calculated as 2-(ΔCt). All cDNA samples were amplified in 
triplicate.
Table 2. Mature microRNA primer sequence for qRT-PCR.



















All data are represented as mean ± SEM and statistical comparison between two 
groups was performed using the Student’s t test. When comparing more than two 
groups one way ANOVA was used followed by the post hoc Bonferroni’s multiple 
comparison test in Graph-Pad Prism Version 5 (GraphPad Software, Inc., La Jolla, 




Satellite cells differentiate into myotubes or enter quiescence. 
Human satellite cells were isolated and cultured from enzymatically dissociated mus-
cle tissue. Initial passages comprised of heterogeneous cell populations. At passage 
8, satellite cells were cloned by single cell sorting. Differential Interference Contrast 
imaging showed proliferating satellite cells at passage > 8, and after 5 days of dif-
ferentiation when part of the satellite cells fused and formed myotubes while another 
part remained mononuclear (Fig. 1A-B). Clonal satellite cells uniformly expressed 
Pax7 and Desmin during proliferation (Fig. 1C). Five days after differentiation, Pax7 
positive nuclei were limited to, and increased in the remaining mononuclear satellite 
cells (Fig. 1D). Desmin expression on the other hand, was increased in myotubes.
Figure 1. Human satellite cells differentiate into myotubes or go into quiescence. (A-B) Differential Inter-
ference Contrast image of (A) cloned proliferating satellite cells (T0) and (B) at day 5 after differentiation (T5). 
(C-D) Immunofluorescent staining for Pax7 (red) and Desmin (green) of (C) proliferating satellite cells and (D) 
at day 5 after differentiation. All satellite cells at T0 express both Pax7 and Desmin. After differentiation only the 
mononuclear satellite cells are highly positive for Pax7 while the myotubes are highly positive for Desmin. (E) 
Analyses by TissueFAXS shows that the mean fluorecent intensity of Pax7 per nuclei increases after differen-
tiation. (F-G) Immunofluorescent staining for Pax7 and Ki67 (green) of (F) proliferating satellite cells and (G) 
5 days after differentiation. (H) Analyses by TissueFAXS shows that the percentage Pax7/Ki67 positive nuclei 
decreased after differentiation. Nuclei are counterstained with DAPI (blue). Scalebars are 100 µm (N = 3; data 




During proliferation the percentage Ki67/Pax7 double positive nuclei was 27.7 ± 7.2 
%. Five days after differentiation however, the percentage Ki67/Pax7 double positive 
nuclei decreased to 2.8 ± 0.8 % (Fig. 1E-G; * p = 0.04).
Myotubes and quiescent satellite cells have distinct regulatory factors
While the expression of Pax7 was limited to nuclei of mononuclear quiescent satellite 
cells after differentiation (Fig. 1D), the expression of the transcription factors MyoD 
and Myogenin was increased in nuclei in myotubes (Fig. 2A-B). Also the adult muscle 
marker Myosin was increased in myotubes (Fig. 2C). After differentiation, we
Figure 2. Myotubes and quiescent satellite cells have distinct regulatory factors. (A) Immunofluorescent 
staining of differentiated satellite cells for MyoD (red) and Desmin (green) shows that only the nuclei of myo-
tubes expressed MyoD. (B) Immunofluorescent staining of differentiated satellite cells for Myogenin (red) and 
Desmin (green) shows that only the nuclei of myotubes expressed Myogenin. (C) Immunofluorescent staining 
of differentiated satellite cells for Myosin (red) and Desmin (green) shows that myotubes express both Myosin 
and Desmin. Nuclei are counterstained with DAPI (blue). Scalebars are 100 µm. (D) Quantitative gene expres-
sion analysis of proliferating satellite cells, myotubes and quiescent satellite cells shows a decreased PAX7 
expression in myotubes compared to proliferating satellite cells, (E) an increased MYOD1 expression in both 
myotubes and quiescent satellite cells compared to proliferating satellite cells, (F) and no significant change 
in MYL1 and (G) MYL3 expression. (N = 6; data are represented as means ± SEM; * p = 0.02; ** p < 0.01).
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separated myotubes from quiescent satellite cells, sorted proliferating satellite cells 
and quiescent cells, and analysed the three cell fractions by qRT-PCR. In myotubes 
PAX7 expression had decreased 0.24 ± 0.08 fold compared to proliferating satellite 
cells, and MYOD1 expression had increased 2.41 ± 0.23 fold compared to prolifera-
ting satellite cells (Fig. 2D-E; ** p < 0.01). In quiescent satellite cells however, PAX7 
expression did not change significantly, while MYOD1 expression also increased 1.89 
± 0.14 fold compared to proliferating satellite cells (* p = 0.02). Though Myosin 
expression increased in myotubes at protein level, gene expression of both MYL1 
and MYL3 did not change significantly in either myotubes or quiescent satellite cells 
compared to proliferating satellite cells (Fig. 2C; F-G).
MicroRNA expression in myotubes and quiescent satellite cells
After differentiation, we separated myotubes from quiescent satellite cells, and sor-
ted both proliferating satellite cells and quiescent cells. We compared the microRNA 
expression from these cell fractions by Agilent microRNA microarray. After differen-
tiation of satellite cells, we identified four microRNAs that were highly upregulated 
in myotubes compared to proliferating satellite cells (Fig. 3A). In quiescent cells on 
the other hand, we did not find any significantly upregulated microRNAs compared to 
proliferating satellite cells (Fig. 3B). Strikingly, in general all microRNAs were decre-
ased in quiescent cells compared to proliferating satellite cells. Among these were 
microRNA-106b, microRNA-25, microRNA-29c and microRNA-320c that were sig-
nificantly downregulated (Table 3).
The downregulation of these microRNAs was confirmed by qRT-PCR; microRNA-
106b decreased 0.23 ± 0.15 fold, microRNA-25 decreased 0.42 ± 0.13 fold, 
microRNA-29c decreased 0.29 ± 0.15 fold, microRNA-320c decreased 0.18 ± 0.06 
fold (Fig. 4; ** p < 0.01; * p < 0.05).
Figure 3. MicroRNA microarray comparing proliferating satellite cells to myotubes and quiescent 
satellite cells. In myotubes microRNA-1, microRNA-133, microRNA-206 and microRNA-486 are significantly 
upregulated compared to proliferating satellite cells. Quiescent satellite cells show a global downregulation of 




Table 3. Fold change of microRNA expression in myotubes and quiescent satellite cells 


















RNaseL involvement in quiescent satellite cells
Besides this overall decrease of microRNA expression in quiescent satellite cells, we 
also found that total mRNA had decreased.  In quiescent satellite cells mRNA decre-
ased 0.29 ± 0.07 fold compared mRNA in to the same number of proliferating satellite 
cells (p = 0.02). Therefore, another post-transcriptional mechanism might be involved 
in regulating quiescence in satellite cells. RNaseL is an activatable endonuclease 
that cleaves single-stranded viral, ribosomal, and mRNAs and thus causes an over-
all reduction of protein synthesis [113]. Overexpression of active RNaseL prevents 
myotube formation [114,115]. Thus, we argued that RNaseL could also be involved in 
maintaining or promoting quiescence in satellite cells.
In quiescent satellite cells RNaseL was located in the nuclei (Fig. 5A, arrowheads), 
while RNaseL was not detectable in the nuclei of myotubes (Fig. 5A, arrow). We also 
analysed RNASEL by qRT-PCR in the separated cell fractions, proliferating satellite 
cells, myotubes and quiescent satellite cells. The RNASEL expression had decreased 
0.08 ± 0.03 fold in myotubes compared to proliferating satellite cells (*** p < 0.001), 
while quiescent satellite cells it did not change significantly compared to proliferating 




In the current study, we investigated microRNA involvement in the differentiation of 
human satellite cells. Our main finding is that during differentiation of human satel-
lite cells, microRNAs are globally downregulated in quiescent satellite cells, while in 
myotubes the expression of myomiRs is increased. 
Another major finding is that upon differentiation, Pax7 positive cells stop prolifera-
ting and enter quiescence (Fig. 1 C-G). Previously we have shown that Pax7 expression 
per cell increases [112]. Taken together, our results suggest that two distinct popula-
tions of Pax 7-expressing satellite cells exist, that represent different stages: prolife-
rative satellite cells versus non-proliferative satellite cells. These non-proliferative 
satellite cells arise during myogenesis. They likely have in vivo counterparts which 
are known as reserve cells [89] or quiescent satellite cells [85,90,91,116,117]. In vivo, 
these quiescent satellite cells are important in the maintenance of the regenerative 
capacity of skeletal muscle. They are capable of proliferation, and either differenti-
ate to repair damaged muscle fibers or enter quiescence to maintain the satellite cell 
pool. Therefore, investigating the regulation of both these distinct cell fates of satel-
lite cells, i.e. myotube formation or entering quiescence, is important for regenerative 
medicine. However, to our knowledge, microRNA expression in quiescent satellite 
cells had not been addressed yet. Furthermore, studies on microRNAs in differentia-
ting satellite cells do not distinguish myotubes from quiescent satellite cells. There-
fore, the microRNAs which have been previously described to be involved in satellite 
cell differentiation, i.e. myomiRs such as microRNA-1 [105], micro-RNA-133 [100], 
microRNA-206 [92,102] and microRNA-486 [104], are in fact involved in myotube 
Figure 4. MicroRNA expression in 
quiescent satellite cells. Quantita-
tive microRNA expression analysis 
in proliferating satellite cells and qui-
escent satellite cells shows a decre-
ased expression of microRNA-106b, 
microRNA-25, microRNA-29c and 
microRNA-320c in quiescent satellite 
cells compared to proliferating satellite 
cells. (N = 6; data are represented as 




formation. We confirmed this, moreover, by showing that these microRNAs are not 
involved in quiescent satellite cells as such (Fig. 3; Table 3). 
Our study shows that both proliferation and microRNA-106b and microRNA-25 are 
significantly decreased in quiescent human satellite cells. In neural stem/progeni-
tor cells isolated from adult mice, it has been shown that an overexpression of the 
microRNA-106b ~25 cluster is involved in promoting proliferation, whereas a knock-
down of this cluster decreases proliferation [118]. However, in human HEK293 cells, 
microRNA-25 itself inhibits proliferation [119]. In our study both microRNA-25 and 
proliferation are decreased. Therefore, the effect of microRNA-25 on the proliferation 
of human satellite cells remains unclear.
It has previously been shown that in primary mice myoblasts and in the murine myo-
blast cell line C2C12, microRNA-29c promotes myogenesis [110,111]. It has also 
been shown that microRNA-29c and microRNA-320 promote apoptosis in myocardial 
cells [120]. Our study shows that in quiescent human satellite cells, both microRNA-
29c and microRNA-320c are decreased; therefore it seems feasible that in quiescent 
satellite cells both myogenesis and apoptosis are not promoted while quiescence is 
maintained.
In C2C12 cells it had been shown that RNaseL overexpression inhibits myotube for-
mation [114,121]. RNaseL ia activated when a family of 2’,5’-oligoadenylate synthe-
tases bind latent RNase-L resulting in its dimerization and subsequent activation. This 
activated RNaseL cleaves single-stranded viral, ribosomal, and mRNAs [113].
Figure 5. RNaseL expression in quiescent satellite cells. (A) Immunofluorescent staining of differentiated 
satellite cells for RNaseL (red) shows that only nuclei of quiescent satellite cells express RNaseL(arrowhead), 
while the nuclei of myotubes do not (arrow). Nuclei are counterstained with DAPI (blue). Scalebar is 100 µm. 
(B) Quantitative gene expression analysis of RNASEL in proliferating satellite cells, myotubes and quiescent 
satellite cells shows a decreased expression in myotubes compared to both proliferating and quiescent satellite 
cells. (N = 6; data are represented as means ± SEM; ** p < 0.01; *** p <0.001).
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In addition to its nuclease function, a role for RNase-L in translational regulation 
was recently reported [122]. Furthermore, genetic approaches to manipulate RNaseL 
expression and activity revealed that it exerts potent antiproliferative, proapoptotic, 
and senescence inducing activities [123-126]. Since RNaseL is involved in degra-
ding various RNAs, it might also be involved in microRNA degradation. This might 
explain part of the global downregulation of microRNAs in quiescent satellite cells. 
On the other hand, it might be that due to the global downregulation of microRNAs 
that RNaseL is no longer degraded, and therefore quiescence is induced. Anyhow, 
the nuclear expression of RNaseL in quiescent satellite cells as opposed to myotubes 
indicates RNaseL involvement in either inhibiting myotube formation or maintaining 
quiescence. 
Although RNaseL might play an active role in the global downregulation of microR-
NAs in quiescent satellite cells, further research should focus on finding the ‘master 
switch’, or other contributing players, that causes this massive downregulation. Little 
is known about a global microRNA downregulation during differentiation, however, 
indications that such a ‘master switch’ might play a role can also be found in oocytes 
and T-cells. Early during development microRNAs are suppressed in oocytes. This is 
likely an early event in reprogramming gene expression during the transition of a dif-
ferentiated oocyte into pluripotent blastomeres of an embryo [127,128]. During anti-
gen induced T-cell differentiation the microRNA profile changes dynamically; also in 
effector T-cells a global downregulation of microRNAs is observed [129].
CONCLUSION
In the current study, we show that microRNAs are globally downregulated in human 
satellite cells entering quiescence compared to proliferating human satellite cells. 
Furthermore, several microRNAs which have previously been described to be 
involved in satellite cell differentiation are involved in myotube formation rather than 
satellite cells entering quiescence. Given the importance of quiescent satellite cells in 
skeletal muscle development and regeneration, it is imperative to distinguish between 
myotubes and quiescent satellite cells when investigating skeletal muscle develop-
ment. Especially in microRNA studies, since this study shows that microRNAs are 
globally downregulated in quiescent human satellite cells; in particular microRNA-
106b, microRNA-25, microRNA-29c and microRNA-320c.
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Innovative strategies based on regenerative medicine, in particular tissue enginee-
ring of skeletal muscle, are promising for treatment of patients with skeletal muscle 
damage. However, the efficiency of satellite cell differentiation in vitro is suboptimal. 
MicroRNAs are involved in the regulation of cell proliferation and differentiation. We 
hypothesized that transient overexpression of microRNA-1 or microRNA-206 enhan-
ces the differentiation potential of human satellite cells by downregulation quiescent 
satellite cell regulators, thereby increasing myogenic regulator factors.
To investigate this, we isolated and cultured human satellite cells from muscle biop-
sies. First, through immunofluorescent analysis and qRT-PCR, we showed that in 
satellite cell cultures low Pax7 expression is related to high MyoD expression upon 
differentiation, and subsequently more extensive sarcomere formation, i.e. muscle 
differentiation, was detected. Second, using qRT-PCR, we showed that microRNA-1 
and microRNA-206 are robustly induced in differentiating satellite cells. Finally, a 
gain-of-function approach was used to investigate microRNA-1 and microRNA-206 
potential in human satellite cells to improve differentiation potential. As a proof of 
concept this was also investigated in a three dimensional bio-artificial muscle con-
struct. After transfection with microRNA-1, the number of Pax7 expressing cells 
decreased compared to the microRNA-scrambled control. In differentiated satellite 
cell cultures transfected with either microRNA-1 or microRNA-206, the number 
of MyoD expressing cells increased and α-sarcomeric actin and myosin expression 
increased compared to microRNA-scrambled control cultures. Also in a three dimen-
sional bio-artificial muscle construct an increase in MyoD expression occurred.
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INTRODUCTION
Skeletal muscle tissue damaged by prolonged denervation, caused by facial paraly-
sis, often requires extensive surgical reconstruction. Autologous donor muscle can 
be utilized to repair some muscle damage. However, only one or two muscles can be 
reanimated, patients are often hindered by autostatic syndrome [5], and genuine rege-
neration is not achieved [6,7]. Innovative strategies based on regenerative medicine, 
in particular tissue engineering of skeletal muscle, are promising for treatment of 
patients with facial paralysis. Engineered muscle tissue may be customized according 
to the individual patient’s desire and offers an opportunity for patients to improve 
physical and psychological symptoms, without causing significant scarring and donor 
site morbidity.
Muscle tissue has its own endogenous repair and maintenance system which is based 
on myogenic progenitor cells, i.e. satellite cells. Upon stimuli, such as damage, satel-
lite cells proliferate and differentiate, which contributes to regeneration of damaged 
muscle [82-85]. The regenerative capacities of human satellite cells derived of skeletal 
muscle appear to make them a suitable source for tissue engineering [130]. However, 
myogenesis, i.e. efficient differentiation of human satellite cells towards adult skeletal 
muscle, remains a major hurdle in vitro. Moreover, with increasing age, the popula-
tion of satellite cells per myofiber decreases [131,132]. Furthermore, the myogenic 
capacity of satellite cells in vitro decreases [132-134]. Therefore, tissue engineering 
of skeletal muscle from autologous satellite cells will be impaired for elderly patients. 
Due to donor variation, the efficiency of tissue engineering of skeletal muscle will 
vary between individual patients [135,136]. Therefore, novel approaches to improve 
myogenesis are mandatory to augment tissue engineering of human skeletal muscle. 
The process of myogenesis is strongly regulated by epigenetic factors, in particular by 
microRNAs [94,98,100,137,138]. Therefore, we hypothesized that microRNAs could 
contribute to improve tissue engineering of human skeletal muscle for future clinical 
application. 
MicroRNAs are small, non-coding RNAs, 20-22 nucleotides in length, involved in 
post-transcriptional gene regulation through inhibition of protein translation or enhan-
cing messenger RNA degradation. Thereby, they also offer great potential as a tool 
to modify cell fate and function [9]. MicroRNA-1 and microRNA-206 appear promi-
nent in myogenesis through regulation of the pairedbox genes PAX3 and PAX7 [102-
104]. These pairedbox genes are quiescent satellite cell regulators which are essential 
in myogenesis. They function upstream of both myogenic regulator genes MYOD1 
44
CHAPTER 4
and MYF5 to initiate proliferation and muscle differentiation [84,139-141]. If Pax7 is 
either overexpressed in satellite cells, or if its expression is prolonged, MyoD expres-
sion is inhibited and the onset of myogenesis delayed, which prevents muscle dif-
ferentiation [142]. In satellite cells, microRNA-1 and microRNA-206 downregulate 
Pax7 such that MYOD1 is no longer inhibited, and muscle differentiation progresses. 
Another microRNA involved in myogenesis is microRNA-133 that promotes prolife-
ration through repressing Serum Response Factor, which results in inhibited muscle 
differentiation [100].
We propose to modify the microRNA profile of satellite cells to facilitate tissue 
engineering of skeletal muscle, which is a novel concept in regenerative medicine. 
It offers an opportunity to transfect satellite cells with a pre-microRNA or anti-
microRNA in order to modulate myogenesis. By transfecting murine satellite cells 
with anti-microRNA-133, the contractile force of a bio-artificial muscle increased 
[143]. However, the potential of human satellite cells transfected with microRNA-1 
or microRNA-206 in tissue engineering remains to be investigated. 
This current study aims to investigate whether modulation of human satellite cells 
through microRNA-1 and microRNA-206 could contribute to the differentiation 
potential of human satellite cells in a three dimensional bio-artificial muscle model, 
thereby improve tissue engineering of human skeletal muscle. 
Our hypothesis is that transient overexpression of microRNA-1 or microRNA-206 
enhances the differentiation potential of human satellite cells by downregulation qui-
escent satellite cell regulators, thereby increasing myogenic regulator factors. 
MATERIALS AND METHODS
Satellite cell isolation and culture
Muscle biopsies were obtained from 6 healthy donors, undergoing reconstructive sur-
gery. The age of the donors was 49.5 ± 8 years (30 to 60 years). The study protocol 
was approved by the institutional medical ethics committee, and patients gave their 
informed consent. Satellite cells were isolated with 0.04 mg/ ml (0.16 Collagenase 
Wünsch units/ml) Liberase Blendzyme 3 (Roche Applied Science, the Netherlands) as 
described previously [112]. Proliferation medium consisted of Dulbecco’s Modified 
Eagle Medium (DMEM) (Invitrogen/Gibco, CA, USA), 20 % Fetal Bovine Serum 
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Differentiation medium (DM), contained DMEM, 2 % FBS, 1 % penicillin/strepto-
mycin, 1 % Insulin-Transferrin-Selenium-A (100x) (Invitrogen) and 0.4 μg/ml dexa-
methason (Sigma-Aldrich). Medium was refreshed three times per week. Cells were 
plated at 5.0 x 103 cells/cm2 in culture flasks precoated with 1 % gelatine/PBS for 30 
min. When cells reached 70 % confluence they were enzymatically harvested using 
Accutase (Invitrogen) and passaged.
Passage number (Px) was defined as the xth sequential harvest of a subconfluent cell 
population. All experiments were performed using P8-15.
Transfection with microRNA-1 and microRNA-206
For gain-of-function studies, pre-microRNA molecules specific for the mature human 
microRNA-1 sequence, UGGAAUGUAAAGAAGUAUGUAU (pre-miR for hsa-
miR-1, PM10617), and microRNA-206 sequence, UGGAAUGUAAGGAAGUGU-
GUGG (pre-miR for hsa-miR-206, PM10409; both Ambion/Applied Biosystems, 
Foster City, CA), were transfected with siPORT NeoFX transfection agent (Ambion) 
into satellite cells in accordance to the manufacturer’s protocol. Briefly, the transfec-
tion agent was diluted in Opti-MEM I (Gibco) and after 10 min mixed with 50 nM of 
the microRNA, or with 50 nM scrambled microRNA control (a random, inert nucleic 
acid sequence). After incubating for 15 min, the mixture was dispensed into gelatin 
precoated tissue culture flasks. Cells were added to each flask at 1.0 x 104 cells/cm2, 
and cultured in PM for 24 hours. After 24 hours, PM was refreshed and cells were 
cultured another 24-48 hours until they reached 100 % confluence.
Bio-artificial muscle construct engineering
Bio-artificial muscle construct were cultured as previously described [144]. Briefly, 
house-shaped pieces of Velcro were glued to the bottom of a 6 wells plate 12 mm 
apart, sterilized with ethanol (70 %) and exposure to UV for 15 min. A gel mixture 
was prepared on ice by mixing 50 % Collagen type I (3,44 mg/ml, BD Biosciences), 
39 % PM, 3 % 0.5 M NaOH (Sigma-Aldrich), 8 % growth factor reduced Matrigel® 
(BD Biosciences). Satellite cells transfected with microRNA-1, microRNA-206 or 
the scrambled control were harvested and mixed at a concentration of 4.5 x 106 per ml 
gel. Then, 350 µl of gel mixture was pipetted in and between the Velcro attachment 
points. After 1 hour gelation, 3 ml PM was added which was replaced after 24 hours 




Cells were cultured on Thermanox® coverslips, Lab-Tek chamber slides or 96 wells 
plates (all NUNC Brand Products, Roskilde, Denmark) coated with 1 % gelatine. At 
100 % confluence, cells were fixed or cultured for an additional five days in DM and 
subsequently fixed in 2 % paraformaldehyde (PFA) at room temperature for 10 min. 
A permeabilization step was performed with 0.5 % Triton X-100 (Sigma-Aldrich) in 
PBS at room temperature for 10 min. Non-specific binding-sites were blocked with 
10 % Goat serum in PBS for 30 min. Cells were incubated with the primary antibody 
in PBS and 2 % serum at room temperature for 60 min or at 4 °C overnight. The 
primary antibody consisted of either a myogenic marker, rabbit-anti-human desmin 
(1:100) (Novus Biological, Littleton, USA), a fibroblast marker, mouse anti-human 
MCA1399G (1:100) (AbD serotec, Oxford, UK), a sarcomere component, mouse-anti-
human α-sarcomeric actin IgM (1:200; clone Alpha Sr-1) (Abcam, Cambridge, UK), 
a myogenic transcription factor, mouse-anti-human MyoD (1:100) (Dako, Glostrup, 
Denmark), a sarcomere component, mouse-anti-human myosin (MF20; 1:500) and 
a satellite cell marker, mouse-anti-human Pax7 (1:10) (both Developmental Studies 
Hybridoma Bank, Iowa, USA). After three washes with 0.05 % Tween in PBS the 
cells were incubated with a secondary antibody-cocktail at room temperature for 30 
min. The secondary antibody-cocktail constituted of FITC-conjugated goat-anti-rab-
bit IgG (1:100) (Southern Biotech, AL, USA), Alexa Fluor®488 goat-anti-mouse IgM 
and Alexa Fluor®555 goat-anti-mouse IgG1 or IgG2b (all Invitrogen) (1:300) and 10 
% normal human serum in PBS/DAPI. Samples were mounted in Citifluor AP1 (Agar 
Scientific, Essex, UK). For Odyssey® infrared imaging (LI-COR Biosciences, Lin-
coln, Nebraska, US), the secondary antibody was goat-anti-mouse IrDye800 (1:500 in 
PBS containing DRAQ5 (1:1000) and 10 % normal human serum). Examination was 
performed by immunofluorescent microscopy using a Leica DMRXA microscope and 
Leica Software (Leica Microsystems, Wetzlar, Germany), and further quantification 
was performed by either TissueFAXS using a Zeiss AxioObserver.Z1 microscope and 
TissueQuest Cell Analysis Software (TissueGnostics, Vienna, Austria), or by Odys-
sey® infrared imaging system.
Bio-artificial muscle construct analysis
Contructs were washed in PBS and fixed in 10 % formalin for 1 hour. A permeabili-
zation step was performed with 0.5 % Triton X-100 (Sigma-Aldrich) in PBS at room 
temperature for 30 min. Non-specific binding-sites were blocked 1 % horse serum in 
NET-gel twice for 20 min. Constructs were incubated with mouse-anti-human MyoD 
(1:100) (Dako), rabbit-anti-human desmin (1:100) (Novus Biological) and 10 % 
4
47
MICRORNA-1 AND MICRORNA-206 IMPROVE DIFFERENTIATION 
serum in NET-gel at 4 °C overnight. 
After six washes with NET-gel, the constructs were incubated with Alexa Fluor® 555 
goat-anti-mouse IgG1 (1:300), FITC-conjugated goat-anti-rabbit IgG (1:100) (Sou-
thern Biotech) and 10 % normal human serum in PBS/DAPI at room temperature for 
2 hours. After three washes with NET-gel, constructs were mounted between cover-
glasses with Mowiol. Confocal microscopy was performed using a Leica SP2 AOBS 
CLSM confocal microscoop (Leica Microsystems).
Gene transcript analysis
Total RNA was isolated from approximately 200,000 cells using the Rneasy Kit 
(Qiagen Inc., CA, USA), in accordance to the manufacturer’s protocol. Briefly, a cell 
lysate was made and diluted with an equal volume of ethanol (70 %). RNA was col-
lected on an RNA binding filter by centrifugation. DNA was removed by incubation 
with a DNase I solution at 37 °C for 15 min. The RNA-binding filter was washed 
twice and subsequently the RNA was eluted with 14 μl Elution Buffer. The RNA 
concentration and purity were determined by spectrophotometry (NanoDrop Techno-
logies, Wilmington, NC). For qRT-PCR analysis, total RNA was reverse transcribed 
using the First Strand cDNA synthesis kit (Fermentas UAB, Lithuania). In summary, 
1 μg of total RNA was diluted in a final reaction volume of 20 μl containing random 
hexamer primer (0.5 μg), RiboLock™ Ribonuclease Inhibitor (20 U), 1 mM dNTP 
mix, and incubated at 37 °C for 1 h. The reverse transcription reaction was terminated 
by heating the mixture to 70 °C for 10 min, after which the samples were placed on 
ice. Quantitative RT-PCR analysis was performed in a final reaction volume of 10 
μl, consisting of SYBR Green Supermix (Bio-Rad, Hercules, USA), 0.5 mM primer-
mix (Table 1) and 5 ng cDNA. For analysis of PKT9, Applied Biosystems ‘assay on 
demand’ primer/probe sets were used to detect amplimers of PKT9 (Hs00702289_s1) 
and β-2-Microglobulin (β2M; Hs99999907_m1). Reactions were performed at 95 °C










for 15 s, 60 °C for 30 s, 72 °C for 30 s, for 40 cycles. Analysis of the data was per
formed using Science Detection Software 2.2.2. To determine differences in expres-
sion, Ct-values were normalized against GAPDH-expression using the ΔCt-method 
(ΔCt(gene) = Ct(gene) – Ct(GAPDH or β2M)). Relative expression levels were calculated as 2
-(ΔCt). 
All cDNA samples were amplified in triplicate.
MicroRNA analysis
Total RNA was isolated from approximately 200,000 cells using the mirVana kit 
(Ambion), in accordance to the manufacturer’s protocol. Briefly, a cell lysate was 
made and diluted with 1.25 volumes of ethanol (100 %). Total RNA was collected on 
a RNA binding filter by centrifugation. The RNA concentration and purity were deter-
mined by spectrophotometry (NanoDrop Technologies, Wilmington, NC). cDNA syn-
thesis was performed using the microRNA Reverse Transcription Kit. In summary, 
5 ng of total microRNA was diluted in a final reaction volume of 7.5 μl with 1.5 μl 
microRNA specific RT-primer mix (Table 2) and 3.5 μl RT-master mix, containing 
1 mM dNTP mix, multiscribe RT enzyme, RT Buffer, RNase Inhibitor and water. 
This was incubated at 16 °C for 30 min, 42 °C for 30 min, 85 °C for 5 min, and 
subsequently mixed with 2 μl microRNA specific qRT-primer mix and 10.5 μl water. 
Quantitative RT-PCR analysis was performed with 5 ng cDNA-primer mix and 5 μl 
iTaq Supermix with ROX (Bio-Rad, Hercules, USA). Reactions were performed at 95 
°C for 15 s, 60 °C for 60 s, for 45 cycles. Analysis of the data was performed using 
Science Detection Software 2.2.2. To determine differences in expression, Ct-values 
were normalized against RNU6B-expression using the ΔCt-method (ΔCt(microRNA) = 
Ct(microRNA) – Ct(RNU6B)). Relative expression levels were calculated as 2
-(ΔCt). All cDNA 
samples were amplified in triplicate.
Table 2. Mature microRNA sequence for qRT-PCR.





All data are represented as means ± SEM and were analyzed by Student’s t test or ana-
lysis of variance (ANOVA) using Graph-Pad Prism Version 5 (GraphPad Software, 
Inc., La Jolla, CA, USA).
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RESULTS
The balance between quiescent satellite cells and myotubes during 
myogenesis
Satellite cells were isolated and cultured from enzymatically dissociated muscle tis-
sue. Initial passages comprised of heterogeneous cell populations, but at passage 8 
satellite cells had nearly reached homogeneity (Fig. 1A). Over 95 percent of the cells 
expressed the satellite cell marker desmin. The remaining desmin negative cells were 
most likely residual fibrobasts (Fig. 1B). 
Figure 1. Satellite cell culture, differentiation and characterization. (A) During passages 8-15, cultured 
cells display a homogeneous morphology, note the triangular shaped cells which are typical for satellite cells, 
by differential interference contrast (DIC) microscopy. (B) An immunofluorescent image of proliferating cells at 
passage 9 double stained for a satellite cell marker Desmin (green) and a fibroblast marker MCA1399G (red). 
Nuclei are counterstained with DAPI (blue). (C) Over 95 percent of the cells expressed the satellite cell marker 
Desmin. Differentiation of confluent satellite cell cultures was induced by switching to differentiation medium. 
Five days after switching to differetiation medium, myotubes were clearly visible by DIC microscopy. All scale-
bars are 100 µm.
Differentiation of confluent satellite cell cultures was induced by switching to dif-
ferentiation medium (DM). Five days after switching to DM, part of the satellite cells 
had differentiated, fused and formed myotubes (Fig. 1C). Approximately 30 percent 
of the satellite cell remained mononucleated. These cells highly expressed Pax7. On 
the contrary, the nuclei of satellite cells that formed myotubes did not express Pax7. 
However, they expressed MyoD, and moreover, myotubes were highly positive for 
desmin, α-sarcomeric actin and myosin (Fig. 2A-D).
Since normally Pax7 is expressed by quiescent satellite cells, we hypothesized that 
satellite cell cultures which contain a relative low percentage of Pax7 expressing cells 
prior to differentiation, are more prone to myotube formation. Indeed, undifferenti-
ated satellite cell cultures that showed 10.3 ± 5.6 % Pax7 expressing cells (Pax7low), 
showed 61.6 ± 4.9 % more MyoD positive cells than satellite cell cultures that showed 
62.3 ± 11.9 % Pax7 expressing cells (Pax7high) (Fig. 3A-B; p = < 0.01). This was 
confirmed at gene expression level, where undifferentiated satellite cell cultures that 
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expressed relative low levels of PAX7 (2-(ΔCT) = 0.003 ± 0.08)  showed 43.5 ± 9.5 % 
higher MYOD1 expression compared to satellite cell cultures that expressed relative 
high levels of PAX7 (2-(ΔCt) = 0.013 ± 0.22) (Fig. 3C-D; p = 0.02).
In these undifferentiated satellite cell cultures, we measured the protein expression of 
the sarcomere components α-sarcomeric actin and myosin using digitalized immunof-
luorescent imaging (i.e. Odyssey®). It showed that both proteins had similar expres-
sion levels in Pax7low and Pax7high cultures. We confirmed this similar expression of 
α-sarcomeric actin (ACTA1) and myosin (MYL1; MYL3) at gene expression level 
(data not shown). However, after differentiation, α-sarcomeric actin expression was 
Figure 2. (A) Differentiation of confluent satellite cell cultures was induced by switching to differentiation 
medium. Immunofluorescent staining of differentiated satellite cell cultures after five days showed myotubes 
that highly expressed Desmin (green). The nuclei of quiescent satellite cells highly expressed Pax7 (red). 
(B) Nuclei that expressed MyoD (red) were of cells that had formed myotubes, expressing Desmin (green). 
Furthermore, myotubes also stained positive for (C) α-sarcomeric actin (green) and (D) Myosin (green). Nuclei 
are counterstained with DAPI (blue). Scalebars A-B are 50 µm and C-D are 100 µm.
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17.7 ± 5,4 %  higher in Pax7low cultures compared to Pax7high cultures (Fig. 4A-B; p = 
0.03). Furthermore, also at gene expression level, ACTA1 expression was 73.6 ± 7.4 
% higher in Pax7low cultures (Fig. 4C; p = 0.01). 
MicroRNA expression during satellite cell differentiation
We determined microRNA-1 and microRNA-206 expression in proliferation, conflu-
ent and differentiated satellite cell cultures. Using qRT-PCR, we showed that both 
microRNAs were upregulated 10-fold when satellite cells reached confluence. During 
myotube formation, microRNA-1 is upregulated an additional 100-fold, and also 
microRNA-206 is upregulated an additional 10-fold. The levels in which microRNA-1 
and microRNA-206 were expressed, were comparable to levels we found in normal 
human skeletal muscle biopsies (Fig. 5A-B).
Effective satellite cell transfection with microRNA-1
Satellite cells were transfected with microRNA-1 or scrambled microRNA for forty-
eight hours. We found that PKT9 (an experimental control gene), was down-regulated 
by 79.5 ± 2.9 % in satellite cell cultures transfected with microRNA-1, compared to 
satellite cell cultures transfected with the scrambled microRNA control. This confir-
med an effective cell transfection. Furthermore, we observed only a 2.0 ± 0.2 % cyto-
toxicity level in transfected satellite cells compared to non transfected satellite cells.
Figure 3. (A) Immunofluores-
cent analyses by TissueFAXS 
showed that there are undif-
ferentiated satellite cell cultu-
res that contain a relative low 
percentage of Pax7 expressing 
cells (Pax7low), and cultures that 
contain a high percentage Pax7 
expressing cells (Pax7high). (B) 
In Pax7low cultures, we showed 
that the percentage MyoD posi-
tive cells was 61.6 ± 4.9% higher 
compared to Pax7high cultures (** 
p = < 0.01). (C) Likewise, quan-
titative gene expression analysis 
of undifferentiated satellite cell 
cultures showed cultures with 
relative low PAX7 expression 
(PAX7low), and cultures with rela-
tive high PAX7 expression (PAX-
7high). (D) Also, in PAX7low cultures we showed 43.5 ± 9.5% higher MYOD1 expression compared to PAX7high 
cultures (* p = 0.02).  (N = 4; data are represented as means ± SEM).
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MicroRNA-1 and microRNA-206 regulate satellite cell differentiation 
potential
Gain-of-function approach was used to investigate the potential of microRNA-1 
and microRNA-206 in human satellite cell differentiation. Transfection of undiffe-
rentiated satellite cells for forty-eight hours with microRNA-1, downregulated Pax7 
protein expression by 43.3 ± 15.8 % compared to the scrambled microRNA control 
(p = 0.02). Transfection with microRNA-206 did not result in a significant decrease 
in Pax7 expression. After transfection for forty-eight hours, satellite cells were con-
fluent and PM was switched to DM. Five days after switching to DM, part of the 
Figure 4. Differentiation of satellite cells in Pax7low and Pax7high cultures. (A-B) Immunofluorescent analy-
ses of α-sarcomeric actin (green) by Odyssey, five days after switching to differentiation medium, showed that 
in Pax7low cultures α-sarcomeric actin expression was 17.7 ± 5,4 % higher compared to Pax7high cultures (* p = 
0.03). (C) Furthermore, quantitative gene expression analysis of differentiated cultures revealed 73.6 ± 7.4 % 
higher ACTA1 expression in Pax7low cultures compared to Pax7high cultures (* p = 0.01). (N = 4; data are repre-
sented as means ± SEM). Scalebars are 500 µm.
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satellite cells differentiated. In these differentiated cultures, MyoD protein expres-
sion had increased 82.0 ± 31.3 % in satellite cells transfected with microRNA-1, 
compared to scrambled microRNA (p = 0.03). MyoD expression was 59.2 ± 32.5 
% increased in satellite cells transfected with microRNA-206 (Fig. 6B; p = 0.04). 
Finally, α-sarcomeric actin expression had increased 51.1 ± 24.7 % in satellite cells 
transfected with microRNA-1 (p = 0.04), and 47.9 ± 26.1 % increased in satellite 
cells transfected with microRNA-206 (Fig. 6C; NS). Myosin expression had incre-
ased 14.2 ± 6.2 % in satellite cells transfected with microRNA-1 (p = 0.03), and 32.1 
± 8.3 % increased in satellite cells transfected with microRNA-206 (Fig. 6D; p = < 
0.01). Cross-striations were observed in differentiated satellite cells transfected with 
microRNA-1, microRNA-206 or the scrambled microRNA. However, no significant 
difference between these groups could be detected.
MicroRNA-206 increases satellite cell differentiation in a three dimensi-
onal bio-artificial muscle construct
Satellite cells transfected with microRNA-1 or microRNA-206 were subsequently 
cultured in a three dimensional bio-artificial muscle construct. Analysis by confocal 
microscopy showed that 26.7 ± 0.6 % of the nuclei in the microRNA-1 transfec-
ted muscle constructs were MyoD positive, and 31.7 ± 2.1 % of the nuclei in the 
microRNA-206 transfected muscle constructs were MyoD positive. Compared to 
cultures transfected with the scrambled microRNA control, the percentage of MyoD 
Figure 5. MicroRNA-1 and microRNA-206 expression in proliferating, confluent and differentiated satel-
lite cells. (A-B) Quantitative microRNA expression analysis showed that both microRNAs were upregulated 
10-fold in confluent satellite cells. Five days after switching to differetiation medium, microRNA-1 is upregulated 
100-fold, and microRNA-206 is upregulated 10-fold. Levels in which microRNA-1 and microRNA-206 were 
expressed, were comparable to levels we found in normal human skeletal muscle biopsies. (N = 4; data are 
represented as means ± SEM).
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expressing nuclei was increased 19.4 ± 1.2 % in cultures transfected with microRNA-1, 
and 31.8 ± 4.5 %  in cultures transfected with microRNA-206 (Fig. 7; ** p < 0.01).
DISCUSSION
The current study set out to investigate whether modulation through microRNA-1 and 
microRNA-206 of human satellite cells could positively influence myogenesis. One 
major finding is that transient overexpression of microRNA-1 or microRNA-206 in 
satellite cells enhances differentiation potential by downregulation the satellite cell 
marker Pax7, thereby increasing the myogenic regulator factor MyoD and enhancing 
myogenic potential. Also in satellite cells cultured in a three dimensional bio-artificial 
muscle construct, this enhancement occurs. Moreover, sarcomere components such 
as α-sarcomeric actin and myosin become more abundant in microRNA transfected 
satellite cells.
Figure 6. The effect of 
microRNA-1 and microRNA-206 
on satellite cells. (A) Analysis by 
TissueFAXS showed a decrease 
of Pax7 expressing cells by 43.3 
± 15.8 % in proliferating satel-
lite cell cultures transfected with 
microRNA-1 for forty-eight hours, 
compared to cultures transfected 
with the scrambled microRNA 
control (* p = 0.02). There was 
no significant decrease in the 
percentage of Pax7 expressing 
cells in cultures transfected with 
microRNA-206. (B) After transfec-
tion for forty-eight hours, satellite 
cells reached confluence  and 
differentiation was initiated by swi-
ching to differentiation medium for 
five days. In these differentiated 
cultures, the percentage MyoD 
expressing cells was increased 
82.0 ± 31.3 % in cultures transfected with microRNA-1, and increased 59.2 ± 32.5% in cultures transfected with 
microRNA-206 compared to cultures transfected with the scrambled microRNA control (* p = 0.03 and p = 0.04 
respectively). (C) Immunofluorescent analysis by Odyssey of α-sarcomeric actin showed an increase of 51.1 ± 
24.7 % in cultures transfected with microRNA-1 compared to cultures transfected with the scrambled microRNA 
control (* p = 0.04). There was no significant increase in α-sarcomeric actin expression in cultures transfected 
with microRNA-206. (D) Myosin expression increased 14.2 ± 6.2 % in cultures transfected with microRNA-1, 
and increased 32.1 ± 8.3 % in cultures transfected with microRNA-206 compared to cultures transfected with 
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Our finding that when Pax7 expression is low in proliferating satellite cells, MyoD 
expression is high, implies that  these cells are geared up for myogenic differentiation 
i.e. myotube formation. This results in an increased upregulation of the sarcomere 
component α-sarcomeric actin, and more efficient myotube formation during differen-
tiation. This differentiation process is caused by activation of the myogenic regulator 
factors MyoD and Myf5, after which Pax7, a transcription factor that inhibits dif-
ferentiation and maintains quiescent satellite cell state, is downregulated [145,146]. 
Our results show that microRNA-1 and microRNA-206 are highly upregulated during 
differentiation of human satellite cells. Through transient transfection of human satel-
lite cells with microRNA-1 and microRNA-206, we show that microRNA-1 corre-
lates with a downregulation of Pax7, resulting in an upregulation of MyoD and sub-
sequently, a higher α-sarcomeric actin and myosin expression. The explanation for 
this increased differentiation is that microRNA-1 and microRNA-206 are transcribed 
simultaneously with MYOD1, which is upregulated during differentiation [103,137]. 
MicroRNA-1 and microRNA-206 bind to the 3’UTR of Pax3, thereby downregula-
ting Pax3. Since Pax3 is responsible for preserving quiescent satellite cell state and 
preventing differentiation, downregulating Pax3 promotes differentiation of satellite 
cells [103]. Furthermore, microRNA-1 and microRNA-206 also bind to the 3’UTR 
of Pax7, downregulating Pax7 and even further promoting differentiation in satel-
lite cells [102,104]. Although we did not find a significant downregulation of Pax7 
upon transfection with microRNA-206, satellite cells did show a significant upregu-
lation of MyoD, and also a higher α-sarcomeric actin and myosin expression. This 
discrepancy in microRNA-206 regulation of Pax7 might be caused by differences, 
such as rodent versus human or cell line versus primary cells [147,148], which makes 
translation to primary human cells difficult. Furthermore, heterogeneity with res-
pect to function, behavior and different subsets within the satellite cell population 
[43,135,139,149,150] might be responsible for this discrepancy. The heterogeneity is 
caused by different capacities of satellite cells; they are capable of regenerating mus-
cle fibers and meanwhile replenishing their own pool of progenitor cells [90,91]. On 
the other hand, these qualities of simultaneous regeneration and self renewal render 
satellite cells highly suitable for tissue engineering. 
Furthermore, transient transfection with microRNA-206 alone may not be sufficient 
to downregulate Pax7 significantly, but it might be possible that a slight downre-
gulation at an earlier timepoint, is sufficient to influence downstream effects, such 
as upregulating MyoD, α-sarcomeric actin and myosin. Also, in recently published 
studies, microRNA-1 and microRNA-206 are co-administered to repress Pax7 [102], 
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which may indicate that transfection with both microRNAs is necessary to have a 
significant effect.
Remarkably, we were unable to show a loss-of-function after transient transfection 
with anti-microRNA antisense molecules specific for the mature microRNA-1 and 
microRNA-206 sequence (anti-miR for hsa-miR-1, AM10617; anti-miR for hsa-
miR-206, AM10409, Ambion). The expression of Pax7, MyoD, α-sarcomeric actin 
or myosin did not change significantly in either proliferating satellite cell cultures 
or differentiated satellite cell cultures (data not shown). Most likely, the antisense 
molecules cannot be offered in sufficient amounts to reach the threshold necessary to 
exert a functional or measurable effect as a result of the high increase in endogenous 
microRNA-1 and microRNA-206 in differentiating human satellite cells, and the tran-
sient character of transfection in our study.
Our results demonstrate that microRNA-1 and microRNA-206 promote satellite cell 
differentiation through a downregulation of Pax7 and/or an upregulation of MyoD. 
However, transfection with either microRNA-1 or microRNA-206 solely, was not 
sufficient to trigger myotube formation in proliferating or even confluent satellite 
cells. For that to occur, confluency and switching to differentiation medium was still 
required. Thus, microRNA-1 and microRNA-206 enhance muscle differentiation, but 
require other mediators to initiate myotube formation.
Several microRNAs have been identified that are involved in skeletal muscle proli-
Figure 7. The effect 
of microRNA-1 and 
microRNA-206 on satellite 
cells in a three dimensi-
onal bio-artificial muscle 
construct. The percentage 
of MyoD expressing cells 
increased 19.4 ± 1.2 % in 
cultures transfected with 
microRNA-1, and 31.8 ± 
4.5 % in cultures transfec-
ted with microRNA-206 
compared to cultures trans-
fected with the scrambled 
microRNA control (** p 
< 0.01). (N = 3; data are 
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feration and differentiation [94,95]. Besides the pronounced role for microRNA-1 
and microRNA-206, there is involvement of microRNA-27. Through downregulating 
Pax3, microRNA-27 forces satellite cells to start differentiation [109]. Furthermore, 
for tissue engineering applications, transfection with microRNAs offers a novel tool 
for modulating efficient cell function. MicroRNA-133 is involved in maintaining pro-
liferation of satellite cells through repressing Serum Response Factor. The inhibition 
of microRNA-133 in murine satellite cells decreased their proliferation [100,148]. 
In a three dimensional model, i.e. a bio-artificial muscle [144,148], this inhibition 
of microRNA-133 improved expression of a differentiation marker Mef2 and more-
over and improved contractile force [143]. Upon culture in a three dimensional bio-
artificial muscle construct, satellite cells transfected with microRNA-206 showed an 
increased MyoD expression. Therefore, we conclude that in a scaffold consisting of 
extracellular matrix microRNA-206 improves the generation of myotubes. After con-
firming the augmenting effect of microRNAs in two dimensional cultures thoroughly, 
we show that this also occurs in a three dimensional set-up, paving the way for future 
functional in vitro and in vivo experiments.
We have shown that microRNA-1 and microRNA-206 improve differentiation of 
human satellite cells. However, in optimizing differentiation, it is key to prevent com-
plete depletion of the pool of quiescent satellite cells, known as reserve cells [151]. 
This population of satellite cells per myofiber naturally decreases with increasing age 
in vivo, as does their myogenic capacity [131,132,152]. Therefore, to promote tissue 
engineering of skeletal muscle from autologous satellite cells novel approaches such 
as microRNAs contribute to improve tissue engineering of human skeletal muscle for 
clinical application. Furthermore, for in vivo implantation, preservation of a pool of 
progenitor cells and their regenerative capacity in the tissue engineered construct is 
important. Transient transfection is a good option, for it modulates satellite cells in 
entering the differentiation program, without being a complete knockdown of qui-
escent satellite cell preserving factors. It merely provides a kick start in differenti-
ation of satellite cells during tissue engineering of skeletal muscle. Maintaining the 
balance between genetic regulatory transcription factors and epigenetic regulatory 
microRNAs is vital. Therefore, in future studies, we aim to identify players that are 
responsible for the balance between regeneration of skeletal muscle and quiescence 
of satellite cells.
In conclusion, we show that microRNA-1 and microRNA-206 improve human satel-
lite cell differentiation potential. And this represents a novel approach for tissue engi-
neering of human skeletal muscle for the benefit of patients with facial paralysis.
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Facial paralysis is a physically, psychologically and socially disabling condition. 
Innovative treatment strategies based on regenerative medicine, in particular tissue 
engineering of skeletal muscle, are promising for treatment of patients with facial 
paralysis.
The natural source for tissue engineered muscle would be muscle stem cells, i.e human 
satellite cells (SC). In vivo, SC respond to hypoxic, ischemic muscle damage by acti-
vation, proliferation, differentiation to myotubes and maturation to muscle fibers, 
while maintaining their reserve pool of SC. Therefore, our hypothesis is that hypoxia 
improves proliferation and differentiation of SC. During tissue engineering a 3D con-
struct, or implanting SC in vivo, SC will encounter hypoxic environments. Thus, we 
set out to test our hypothesis on SC in vitro. During the first five passages hypoxically 
cultured SC proliferated faster than their counterparts under normoxia. Moreover, also 
at higher passages, a switch from normoxia to hypoxia enhanced proliferation of SC.
Hypoxia did not affect the expression of SC markers desmin and NCAM. Yet, the 
average surface expression per cell of NCAM was downregulated by hypoxia and it 
also downregulated the gene expression of NCAM. The gene expression of the myo-
genic transcription factors PAX7, MYF5 and MYOD1 were upregulated by hypoxia. 
Moreover, gene expression of structural proteins α-sarcomeric actin (ACTA1), and 
myosins MYL1 and MYL3 was upregulated by hypoxia during differentiation. This 
indicates that hypoxia promotes a pro-myogenic shift in SC. Finally, Pax7 expression 
was not influenced by hypoxia and maintained in a subset of mononucleated cells, 
while these cells were devoid of structural muscle proteins. This suggests that during 
myogenesis in vitro, at least part of the SC adopt a quiescent, i.e. reserve cells, phe-
notype. In conclusion, tissue engineering under hypoxic conditions would seem favo-




Paralysis of the facial muscles is a physical disabling condition which, due to impaired 
facial expression, leads to significant physical, psychological and social distress. Des-
pite advancing knowledge and improved surgical techniques, outcome of conven-
tional treatment strategies improve the quality of life of patients but genuine rege-
neration is not achieved [4,12,153]. The human face holds 23 paired facial muscles 
and one unpaired, the orbicularis oris muscle [1]. With autologous muscle transplan-
tations, only one or two muscles can be reanimated, subtlety in movement can’t be 
achieved fully, and patients are often hindered by autostatic syndrome [5].  Innovative 
treatment strategies are warranted, such as regenerative medicine. In particular tis-
sue engineering of skeletal muscle is promising for treatment of patients with facial 
paralysis. Engineered facial muscles may be customized to the needs of the individual 
patient which will resolve the patients’ physical symptoms and restore near to normal 
mimical function. 
To accomplish this, a 3 dimensional construct must be engineered consisting of func-
tional skeletal muscle fibers, vasculature and innervation. Combining these premises 
to a clinically functional construct remains a major challenge. For vascularisation, 4 
main techniques are currently subject of investigation: First, through in vivo implan-
tation of a preformed 3 dimensional muscle construct around a vascular pedicle [34]. 
Second, through implantation of myoblasts in a prevascularised fibrin gel [37]. Third, 
through stacking sheets of myoblasts upon a vascular bed, the so called cell sheet 
method [78,80]. And finally through co-culturing myoblasts with endothelial cells 
[25]. To innervate a muscle construct, it is necessary to create a functional neuro-
muscular junction. This could be reached through co-culturing myoblasts and neural 
tissue [72], and by means of electrical stimulation [35].
Muscle tissue has its own endogenous repair and maintenance system which is based 
on myogenic progenitor cells, i.e. satellite cells. The regenerative capacities and myo-
genic characteristics of these satellite cells has been topic of many studies that aim 
to use satellite cells to tissue engineer muscle [85,130,154]. In response to hypoxic 
ischemia in skeletal muscle, e.g. after exercise or injury, satellite cells are activated. 
These activated satellite cells start to proliferate and differentiate, which contributes 
to regeneration of the affected muscle [82,84,145]. 
In tissue engineering functional skeletal muscle, angiogenesis and neurogenesis are 
imperative. However, vascularisation of a tissue engineered muscle construct may not 
be instantly functional after implantation in vivo. Thus, satellite cells in the center of 
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the muscle construct will encounter hypoxia. Therefore, in this study, we focus on the 
influence of hypoxia on myogenesis in vitro.
In general, hypoxia is a crucial limiting factor in tissue engineering of constructs that 
exceed approximately 0.2 mm thickness. In these constructs a steep oxygen concen-
tration gradient occurs, with hypoxic levels inside which may result in cell death after 
implantation [155]. In vivo, skeletal muscle is shown to adapt to a prolonged hypoxic 
environment through upregulating myostatin, causing atrophy [156]. In mesenchymal 
stem cells however, hypoxic- preconditioning in vitro had profound benefits for cell 
survival after implantation [157]. Bovine satellite cells were shown to both proliferate 
and differentiate more efficiently under hypoxia [158]. Yet, species differences may 
exist, and the influence of hypoxia on human satellite cells was not fully investiga-
ted yet. The importance of in vitro research shows from a resent clinical trial where 
myoblasts, i.e. satellite cells, were transplanted into a hypoxic environment of the 
ischemic heart of patients suffering from heart failure. However, echocardiographic 
heart function did not improve and arrhythmia occurred, indicating cellular dysfunc-
tion [159]. In tissue engineering, as in cell therapy, satellite cells will encounter hypo-
xic environments. Therefore, for clinical application of human satellite cells, a better 
understanding of the response of human satellite cells to changes in oxygen level is 
required. In tissue engineering facial muscles, although they are thinner than other 
skeletal muscles, their thickness exceeds 0.2 mm. Hence, satellite cells encounter 
lower oxygen concentrations. Therefore, before applying these muscle constructs in 
vivo, we need to study how satellite cells react to a hypoxic environment. As satellite 
cells in vivo appear to respond to hypoxic muscle damage with activation, prolifera-
tion, differentiation and maturation, while maintaining their reserve pool of satellite 
cells, our hypothesis is that in vitro hypoxia improves proliferation and differentiation 
of human satellite cells.
MATERIALS AND METHODS
Satellite cell isolation
Muscle biopsies were obtained from 8 healthy human donors, 30 to 66 years of age, 
undergoing reconstructive surgery. The age of the donors was 51.7 ± 10.6 years, and 
there were 3 males and 5 females included. The study protocol was approved by our 
institutional ethics committee, and patients gave their informed consent. A muscle bio-
psy of either the latissimus dorsi (3 donors) or the orbicularis oculi muscle (5 donors) 
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was collected in cold (4 °C) phosphate buffered saline (PBS) supplemented with 10 % 
penicillin/streptomycin 50 μg/ml (Sigma-Aldrich, St. Louis, USA). Specimens were 
stripped of any visible connective tissue and fat, weighted and minced. The mus-
cle specimen weight ranged between 200 mg and 800 mg. Enzymatic digestion was 
performed in Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen/Gibco, CA, 
USA) containing 0.04 mg/ ml (0.16 Collagenase Wünsch units/ml) Liberase Blend-
zyme 3 (Roche Applied Science, the Netherlands) at 37 °C for 1 hour. The suspension 
was filtered through a 70 μm filter, 10 % Fetal Bovine Serum (FBS; Invitrogen/Gibco) 
was added to the flow through and centrifuged at 300xg for 10 min at 4 °C after which 
the supernatant was discarded. Lysis-buffer was used to eliminate erythrocytes. After 
2 min on ice, the suspension was centrifuged again at 300xg for 10 min at 4 °C after 
which the supernatant was discarded and the pellet gently resuspended in proliferating 
medium (PM), containing DMEM, 20 % FBS, and 1 % penicillin/streptomycin.
Undigested tissue was subjected to another 2-3 cycles of digestion process. The diffe-
rent cell suspensions were pooled and viable cells were counted using the trypan blue 
exclusion method with a Bürker counting chamber.
Satellite cell culture
Immediately after isolation, the cell suspension was divided into two fractions and 
cultured either under normoxia (21 % O2) or hypoxia (2 % O2) at 37 °C. Cells were 
plated at 5.0 x 103 cells/cm2 on culture flasks precoated with 1 % gelatine. Medium 
was refreshed three times per week.
When cells reached 70 % confluence they, were enzymatically harvested using accu-
tase (Invitrogen), counted with a Coulter Counter and replated at 5.0 x 103 cells/cm2 
on 1 % gelatine precoated flasks.
Myogenic differentiation of satellite cells was induced at 100 % confluence by swit-
ching to differentiation medium (DM), containing DMEM, 2 % FBS, 1 % penicillin/
streptomycin, 1 % Insulin-Transferrin-Selenium-A (100x) (Invitrogen) and 0.4 μg/ml 
dexamethason (Sigma-Aldrich).
Passage number (Px) was defined as the xth sequential harvest of a subconfluent cell 
population. All differentiation experiments were performed using P6 - P15.
The population doubling time was calculated N(t) = C(2)^t/d, N(t) = the number of 
cells at time t d = doubling period C = initial number of cells t = time (days).
A CyQUANT cell proliferation assay (Invitrogen) was performed in accordance to the 
manufacturer’s protocol to determine proliferation.
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Immunofluorescent staining
Cells were cultured in PM on Thermanox® coverslips (NUNC Brand Products, 
Roskilde, Denmark) coated with 1 % gelatine in a 24 wells plate. At 100 % conflu-
ence, cells were washed twice with PBS and either cultured an additional five days in 
DM, or fixed in 2 % paraformaldehyde (PFA) at room temperature for 10 min. Cells 
were dried under a ventilator and stored -20 °C. After thawing, a permeabilization step 
was performed with 0.5 % Triton X-100 (Sigma-Aldrich) in PBS at room temperature 
for 10 min. Non-specific binding-sites were blocked with 10 % Goat serum in PBS for 
30 min. Cells were incubated with the primary antibody in PBS and 2 % Goat serum 
at room temperature for 60 min. The primary antibody consists of either a myoge-
nic marker, rabbit-anti-human desmin (1:100) (Novus Biological, Littleton, USA), 
a proliferation marker, mouse-anti-human Phosphohistone H3 (1:500) (clone 3H10; 
Millipore International Inc., Temecula, CA, USA), a satellite cell marker, mouse-anti-
human NCAM (1:200) (clone MEM-188; Biolegend, San Diago, CA, USA), a fibro-
blast marker, mouse anti-human MCA1399G (1:100) (AbD serotec, Oxford, UK) an 
adult muscle marker, mouse-anti-human myosin (MF20; 1:500) and a satellite cell 
marker, mouse-anti-human Pax7 (1:10) (both Developmental Studies Hybridoma 
Bank, Iowa, USA). After three washes with 0.05 % Tween in PBS the cells were 
incubated with a secondary antibody-cocktail at room temperature for 30min. The 
secondary antibody-cocktail was constituted of FITC-conjungated goat-anti-rabbit 
IgG (Southern Biotech, AL, USA), Texas RedtmX-conjungated donkey-anti-mouse 
IgG (Jackson ImmunoResearch, West Grove, PA, USA), Alexa Fluor® 555 goat-anti-
mouse IgG1 or IgG2b (both Invitrogen) (all 1:200 in PBS/DAPI containing 10 % nor-
mal human serum). After 3 washes with PBS the slides were mounted in Citifluor AP1 
(Agar Scientific, Essex, UK). Examination was performed by immunofluorescent 
microscopy using a Leica DMRXA microscope and Leica Software (Leica Microsys-
tems, Wetzlar, Germany), and further quantification was performed by TissueFAXS 
using a Zeiss AxioObserver.Z1 microscope and TissueQuest Cell Analysis Software 
(TissueGnostics, Vienna, Austria).
Furthermore, for flow cytometry approximately 5x105 cells were resuspended in 100 
ml FACS buffer consisting of PBS (4 salts), 2 mM EDTA and 0.5 % (v/v) FBS. Cells 
were incubated with 5 μl mouse monoclonal FITC-conjugated antibody anti-NCAM 
(Biolegend, San Diego, CA, USA) at 4 °C for 30 min. After two washes with FACS 
buffer, cells were resuspended in 300 μl FACS buffer and examined by FACS analysis 
on a FACSCaliber system (BD Biosciences, San Jose, CA). The analysis was perfor-




At day 0 and day 5, after switching to DM, total RNA was isolated from approxima-
tely 200,000 cells using the Rneasy Kit (Qiagen Inc., CA, USA), in accordance to the 
manufacturers protocol. Briefly, a lysate was made and diluted with an equal volume 
of ethanol (70 %). RNA was collected on an RNA binding filter by centrifugation. 
DNase treatment was performed by incubation with a DNase I solution at 37 °C for 
15 min. The RNA-binding filter was washed twice and subsequently the RNA was 
eluted with 14 μl Elution Buffer. The RNA concentration and purity were determined 
by spectrophotometry (NanoDrop Technologies, Wilmington, NC). For RT-PCR ana
lysis, total RNA was reverse transcribed using the First Strand cDNA synthesis kit 
(Fermentas UAB, Lithuania). In summary, 1 μg of total RNA was diluted in a final 
reaction volume of 20 μl containing random hexamer primer (0.5 μg), RiboLock™ 
Ribonuclease Inhibitor (20 U), 1mM dNTP mix, and incubated at 37 °C for 1 h. The 
reverse transcription reaction was terminated by heating the mixture to 70 °C for 10 
min, after which the samples were placed on ice. RT-PCR was performed in a final 
reaction volume of 25 μl, consisting of 10x Taq polymerase buffer, 0.25 mM dNTP 
mix, 1.5 mM MgCl2, 1 μl primer-mix (Table 1) and 1 U Taq DNA Polymerase. 









PCR reactions were performed at 94 °C for 45 s, 57 °C for 45 s, 72 °C for 1 min, for 
35 cycles. Amplimers were separated in a 2 % agarose gel and stained with 0.5 μg/ml 
ethidium bromide after electrophoresis.
Quantitative RT-PCR analysis was performed in a final reaction volume of 10 μl, con-
sisting of 4.5 μl SYBR Green Supermix (Bio-Rad, Hercules, USA), 0.5 μl primer-mix 
(0.5 mM) (Table 2) and 5 μl cDNA (1 ng/μl). Reactions were performed at 95 °C for 
15 s, 60 °C for 30 s, 72 °C for 30 s, for 40 cycles. Analysis of the data was performed 
using Science Detection Software 2.2.2.
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All data are represented as means ± SEM and were analyzed by Student’s t test or ana-
lysis of variance (ANOVA) using Graph-Pad Prism Version 5 (GraphPad Software, 
Inc., La Jolla, CA, USA).
RESULTS
Proliferation of cells is initially increased under hypoxia
Cells isolated from enzymatically dissociated muscle tissue were divided into two 
fractions, one of which was cultured under normoxia (21 % O2), while the other frac-
tion was cultured under hypoxia (2 % O2) during all passages. On average 1.25 ± 
0.25 x 105 viable cells were isolated per gram of muscle tissue. We observed that the 
morphology of adherent cells was independent of the oxygen level. During low passa-
ges (P0-5), cultures under both oxygen conditions contained both spindle-shaped and 
typical triangular ‘satellite-like’ cells. During these low passages, the cells reached 
confluency twice as fast under hypoxia than under normoxia. The population doubling 
time (PDT) at passage 0-5, determined by cell count, was 8,3 days for normoxic and 
4.3 for hypoxic cultures (p = 0.04, Fig. 1A).
At passage 6-8, in both oxygen conditions, colony forming units (CFU) appeared and 
the cell population became homogeneous, i.e. only the ‘triangular’ shaped cell types 
had remained. This occurred one or two passages later in normoxic than in hypoxic 
cultures. The PDT of cells at high passage (P6-15) decreased 3 to 7 fold and became 




Figure 1. Morphology and Proliferation. (A) During passages (P) 0-5, adhered cells had a heterogeneous 
morphology both at hypoxic and normoxic culture conditions. The population doubling time (PDT) was lower 
for hypoxic cultures (* p = 0.04). (B) During P6-P15, the cultured cells adopted a homogeneous morphology, 
note the triangular shaped cells which are typical for satellite cells. At P6-P15 the PDT decreased, and became 
comparable for both oxygen levels. (C) This was further corroborated by similar staining patterns for phospho-
histone H3 (proliferation, red), Desmin (satellite cells, green) at P6- P15. Nuclei are counterstained with DAPI 
(blue). Quantification of phosphohistone H3 positive cells at P6-P15 by TissueFAXS showed no significant 
difference in proliferation between hypoxic and normoxic culture conditions. (N = 7; data are represented as 
means ± SEM) All scalebars are 100 µm.
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Quantification by TissueFAXS analysis after staining of phosphohistone H3, a marker 
for proliferation, confirmed the lack of significant difference in proliferation of high 
passage cells under normoxia or hypoxia (Fig. 1C).
The CyQUANT assay also showed no significant difference in proliferation rate 
between cells under normoxia or hypoxia at high passage. However, in vivo, hypo-
xic insults actually represent a shift from normoxia to hypoxia, which cause satel-
lite cells to respond either directly or indirectly, with proliferation. We investigated 
the influence of a decrease or increase of oxygen concentration on satellite cells 
that we had cultured under normoxic or hypoxic conditions respectively. Remar-
kably, the transfer of cells from normoxic to hypoxic culture conditions, signifi-
cantly increased their proliferation, with a maximum at 3 days (p = 0.01, Fig. 2).
Desmin and NCAM expression by satellite cells is independent of the 
oxygen level
To further qualify and to quantify satellite cells in our cultures, the expression of des-
min, a myogenic cyotoskeletal protein, was determined by immunofluorescent stai-
ning. Of the cells cultured under normoxia 59.8 ± 13.7 % expressed desmin, and of the 
cells from the same donor, cultured under hypoxia this was 41.1 ± 18.4 % (Fig. 3B). 
Figure 2. Proliferation after switching oxygen concentration. (A) The CyQUANT assay showed an incre-
ased proliferation when cells at high passage (P6-P15) were transferred from normoxia to hypoxia. Hypoxic 
culture conditions significantly stimulated satellite cell proliferation rate by day 3 compared to satellite cells that 
remained in normoxic culture conditions (** p = 0.01). (B) In contrast, the proliferation of cells transferred from 
hypoxia to normoxia remained unchanged. (N = 7; data are represented as means ± SEM).
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This is lower, but does not differ significantly.
The expression of NCAM, which is frequently considered a satellite cell marker, was 
measured by flow cytometry. Only approximately one third (28.4 ± 10.3 %) of the 
satellite cells cultured under normoxia expressed NCAM, while no more than one 
fifth (18.2 ± 6.5 %) of the cells cultured under hypoxia expressed NCAM. The mean 
fluorescent intensity (MFI) of NCAM positive cells in normoxic cultures (27.1 ± 6.6) 
was significantly higher than in hypoxic cultures (11.6 ± 2.0, p = 0.04, Fig. 3C-D).
Together, these findings support that desmin expression by satellite cells is unaffec-
ted by the oxygen level these cells are cultured in. Though the percentage of NCAM 
expressing cells is not affected, the NCAM expression per cell is decreased when 
satellite cells are cultured under hypoxia.
Figure 3. Protein expression analyses. (A) Immunofluorescent image of a proliferating satellite cell at pas-
sage 3 showing positive staining for Desmin (green) and a proliferating satellite cell at passage 3 showing dou-
ble positive staining for Desmin/NCAM (green/red). Nuclei are counterstained with DAPI (blue). (B-C) Quan-
tification of satellite cells during passage 3-15 showed that the fraction of either Desmin expressing cells or 
NCAM expressing cells did not differ between hypoxic and normoxic culture conditions. (D) However, the Mean 
Fluorescent Intensity (MFI), measured by FACS, of NCAM expression was significantly higher in proliferating 
cells cultured under normoxia than hypoxia (* p = 0.04). (N = 8; data are represented as means ± SEM) All 
scalebars are 20 µm.
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Figure 4. Satellite cell purity and fibroblast contamination. Immunofluorescent image of proliferation cell 
cultures at (A) low passage (P3-P4) and (B) high passage (P9-P10) double stained for a satellite cell marker 
Desmin (green) and a fibroblast marker MCA1399G (red). Nuclei are counterstained with DAPI (blue). (C) 
Quantification by TissueFAXS shows that in low passage the percentage satellite cells is low, while the per-
centage of fibroblasts is high. In high passage, the percentage of satellite cells is high, while the percentage of 
fibroblasts is low. Also, there was no effect of hypoxia on satallite cell purity or fibroblast contamination. (N = 4; 
data are represented as means ± SEM) Scalebars are 100 µm.
High satellite cell purity in high passage cultures is not influenced by 
hypoxia
To determine fibroblast contamination in our cell population, we performed a double 
staining of cells in low passage and in high passage with desmin and a fibroblast 
marker MCA1399G, and quantified with the TissueFAXS. In low passage cultures we 
found 13.5 ± 9.3 % desmin positive cells and 75.6 ± 5.8 % fibroblasts (Fig. 4A-C). In 
high passage cultures, we found 91.3 ± 4.1 % desmin positive cells and 1.9 ± 0.7 % 
fibroblasts (Fig. 4B-C). We did not find an effect of hypoxia on fibroblast contamina-
tion. Together, these results show that in low passage cultures, fibroblast contamina-
tion is high, but more importantly, in high passage cultures, fibroblast contamination 
is very low, and cultures mainly consist of satellite cells.
Gene expression of early satellite cell markers seems to be promoted 
by hypoxia
In qualitative gene expression analysis, we found that myogenic regulator factors 
MYF5 and MYOD1 were upregulated in cells cultured under hypoxia, while desmin 
(DES) and α-sarcomeric actin (ACTA1), a marker indicative for structural myogenic 
differentiation, were downregulated in cells cultured under hypoxia. For satellite cell 
markers PAX7 and NCAM there was no difference detected (Fig. 5A). With quan-
tative gene expression analysis, expression of MYOD1 and MYF5 was respectively 
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0.3 and 0.1 fold upregulated in cells cultured under hypoxia compared to normoxia. 
The expression of DES and ACTA1 was downregulated respectively 0.5 and 1.5 fold. 
In contrast, PAX7 was upregultated 0.3 fold, while NCAM was downregulated 0.1 
fold in satellite cells that were cultured under hypoxia (Fig. 5B). The differences at 
gene transcriptional level between cells cultured under normoxia or hypoxia are not 
significant, however, figure 4 represents a trend that under hypoxic culture conditions, 
quiescent satellite cells are promoted.
Myogenic differentiation of satellite cells unaffected by hypoxia
To determine whether satellite cells can form myotubes under hypoxic culture condi-
tions, we exchanged the proliferation medium to differentiation medium when cells 
had reached 100 % confluence in either oxygen concentrations.
We observed that cells in both culture conditions had started to fuse and form multi-
nucleated cells that resembled myotubes within three days after myogenic induction, 
while both at day 3 and day 5 mononucleated cells were still present (Fig. 6A, B, C). 
The multinucleated cells as well as the mononucleated cells expressed desmin (Fig. 
6D, E, F). However, only the multinucleated cells expressed myosin (Fig. 6G, H), 
which confirmed their being myotubes. Furthermore, after five days of differentiation, 
in high passage cell cultures, cross-striations in the myotubes became visible after 
Figure 5. Gene expression analyses. (A) Qualitative gene expression analyses showed the differential regu-
lation of myogenic genes by proliferating satellite cells during passage 3-15. (B) This was corroborated by quan-
titative analyses which showed that PAX7, MYF5 and MYOD1 were upregulated in cells cultured under hypoxia. 
NCAM was downregulated under hypoxia, as were DES and ACTA1. (N = 4; data are represented as means).
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Figure 6. Differentiation of human satellite cells. (A, D, G) In proliferating satellite cells at high passage 
(P6-P15), differentiation was initiated when satellite cells reached 100 % confluence (T0) by swiching to dif-
ferentiation medium. (B, C) Five days after switching to differetiation medium, myotubes were clearly visible by 
differential interference contrast (DIC) microscopy. (D, E, F) Desmin (green) was expressed by undifferentiated 
satellite cells as well as in myotubes, while (G, H) Myosin (red) was solely expressed in myotubes and not by 
mononucleated cells. (I) Cross-striations in myotubes were visible (arrowhead) which are reminiscent of stri-
ated muscle fibers. Nuclei are counterstained with DAPI (blue). (J) During differentiation of satellite cells into 
myoblasts and myotubes, qRT-PCR analysis showed a slight (2 to 20-fold) upregulation of PAX7, the myogenic 
regulator factors MYF5 and MYOD1, and NCAM. Genes of myogenic differentiation DES, ACTA1, MYL1 and 
MYL3 show a strong (up to 150-fold) upregulation. During differentiation, gene regulation was comparable 
between both oxygen conditions, though all genes tended to be more upregulated under hypoxia. The protein 
expression pattern of Myosin concurs with the upregulated gene expression of MYL1 and MYL3 during myoge-
nic differentiation. (N = 4; data are represented as means ± SEM) Scalebars are 100 µm.
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staining for myosin (Fig. 6I). These are the hallmarks of striated muscle.
During differentiation, the morphology of cells was not affected by the oxygen con-
centration: in normoxic culture conditions there was differentiation of satellite cells 
and myotube formation, equally efficient in hypoxic culture conditions based on myo-
tube size and increase in MyoD positive nuclei (data not shown).
Quantitative gene expression analysis showed an upregulation of PAX7, the myoge-
nic regulator factors MYF5 and MYOD1, and NCAM during differentiation. Genes of 
myogenic differentiation such as DES, ACTA1, MYL1 and MYL3 showed a twenty to 
hundred fold upregulation concomitant with myotube formation. During differentia-
tion gene regulation is comparable between both oxygen conditions, though all genes 
are more upregulated by cells cultured under hypoxia (Fig. 6J).
The protein expression pattern of myosin matches the upregulation of MYL1 and 
MYL3, genes responsible for myosin expression.
Myogenic differentiation predisposes a fraction of satellite cells to qui-
escence.
In differentiation medium, part of the satellite cells did not fuse into myotubes. To 
determine whether these cells remained activated satellite cells or whether they 
acquired a quiescent phenotype, an immunofluorescent staining for Pax7 was perfor-
med which was quantified by TissueFAXS analysis. Data showed that during myotube 
formation the percentage Pax7 positive cells did not change (Fig. 7A-B). However, 
the Mean Fluorescent Intensity of Pax7 positive cells had increased (Fig. 7B-C). This 
increase in expression of Pax7 occurred only in the remaining mononucleated cells, 
but not in the myotubes (Fig. 7D). This observation concurs with our findings that 
gene expression of PAX7 is upregulated during myogenic differentiation.
DISCUSSION
The current study set out to investigate the influence of hypoxia on proliferation and 
differentiation of human satellite cells. One major finding is that hypoxia increases 
proliferation of low passage human satellite cells in vitro. Second, satellite cells cul-
tured for multiple passages under hypoxia maintain their myogenic properties and 
enhance their functional capacity of differentiation towards myotubes. Finally, ano-
ther important finding is that during myogenic differentiation in vitro, part of the satel-
lite cells acquired a quiescent phenotype. Taken together, these findings render human 
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satellite cells highly suitable for tissue engineering of skeletal muscle for clinical 
applications.
The proliferation rate of satellite cells during passages 0-5 was higher under hypo-
xia than normoxia, which may imply that satellite cells overgrow fibroblasts quicker 
under hypoxia. At higher passage number, cultures consist of mainly satellite cells and 
proliferation rate increases 3 to 7 fold, irrespective of oxygen level. These observati-
ons in vitro correlate to the response of satellite cells in vivo where hypoxia induces 
vigorous proliferation too [145]. Other studies also reported a beneficial effect of low 
oxygen levels on the proliferation of satellite cells [158,160,161]. However, these 
investigators did not use human satellite cells, but a mouse cell line (C2C12), rat or 
bovine derived or whole muscle fibers. Moreover, in these studies only low passage 
satellite cells were used, and they were subjected to hypoxia after initial normoxic 
culture. In those circumstances we observed a similar, albeit, temporary increase in 
proliferation rate (Fig. 1A; Fig. 2). This is interesting in tissue engineering, because 
large numbers of cells are necessary and these cells must be able to withstand the 
hypoxic surroundings they will encounter to ensure survival. We have shown that 
satellite cells thrive on low levels of oxygen (2 % O2).
A major finding of this study is that in cell populations derived of human skeletal 
muscle, Desminpos/NCAMpos and Desminpos/NCAMneg satellite cell populations are 
present. NCAM is an ‘established’ satellite cell marker which is frequently used to 
purify cell population by cell sorting [41,162]. However, in doing this, the Desminpos/
NCAMneg population is discarded, which are satellite cells capable of differentiation. 
Moreover, a heterogeneous population of satellite cells may have a distinct benefit, 
because their capacity to differentiate and form functional myotubes, i.e. generate 
force, requires supportive cells [43].
The finding that hypoxia decreases NCAM protein levels in satellite cells, was corro-
borated by gene transcript analyses. As it appeared, satellite cells cultured under hypo-
xia harbor a more quiescent state in terms of gene transcripts, while normoxia pro-
motes a more activated myoblast gene expression profile during proliferation (Fig. 5). 
Consistent with our findings is the upregulation of MYOD1 described in primary rat 
and bovine satellite cells cultured under hypoxia [158,163]. However, these published 
results contrast with the murine myoblastic cell line C2C12. Under hypoxia, C2C12 
cells show a delayed myogenic differentiation due to a downregulation of MYOD1, 
which is one of the dominant myogenic transcription factors. This downregulation 
might be caused by an accelerated degradation of MYOD1 at the post-transcription 
level by C2C12 [164]. However, this downregulation of MYOD1 is transient, which 
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Figure 7. Pax7 expression is maintained during myogenic differentiation. (A-B) At day 0 (T0) myogenic 
differentiation was induced in confluent cultures of human satellite cells at high passage (P6-P15) and monito-
red on day 5 (T5). (B) Analyses by TissueFAXS showed that the fraction of Pax7 (red) expressing cells did not 
change during myotube formation. (B-C) However, the Mean Fluorescent Intensity increased in the remaining 
mononucleated cells at T5. (D) Remarkebly, Pax7 was not expressed by nuclei in Desmin (green) positive 
myotubes. This observation concurs with our observation that gene expression of PAX7 was upregulated during 
myogenic differentiation. Nuclei are counterstained with DAPI (blue). Scalebars are 100 µm.
5
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indicates that C2C12 myoblasts can adapt to hypoxic conditions too [163]. This indi-
cates that C2C12 and human satellite cells respond differently to hypoxia. Further-
more, human satellite cells also show donor variation at protein and gene expression 
levels. The donor variation could be a reflection of the functional heterogeneity within 
subpopulations of satellite cells [135,136,141]. Also, due to their different embryonic 
origin, satellite cells derived from craniofacial muscle have properties that set them 
apart from satellite cells derived from limb muscles [48], which might also be a cause 
for our donor variation. Furthermore, there was some age variation in our research 
population. This is important, because when age increases, satellite cell population 
is decreased and their myogenic capacity reduced [131,133,134]. However, in this 
study, we could not relate the donor variation to muscle origin or donor age, because 
the variation was not significant and our population was too small. 
During differentiation, mononucleated satellite cells formed multinucleated myotu-
bes in both oxygen conditions. The myotubes expressed myosin, unlike mononucle-
ated cells. Simultaneously, both MYL1 and MYL3, genes responsible for respectively 
myosin type-1 and myosin type-2 expression were upregulated during differentia-
tion. Both mono- and multinucleated cells expressed desmin, therefore, the remai-
ning mononucleated satellite cells most likely retained the capacity to form myotubes. 
Alternatively, even under myogenic conditions desmin-expressing cells could (de)
differentiate to quiescent satellite cells. This quiescent state was confirmed by the 
enhanced expression of Pax7 during myotube formation by mononucleated cells (Fig. 
7). This also explains the upregulation of PAX7 observed at gene transcript level. We 
can therefore conclude that mononucleated cells maintain their satellite cell character 
Figure 8. Transcriptional lineage of satellite cells. During differentiation of human satellite cells, myotubes 
are formed and gene and protein expression patterns shift towards mature muscle. However, some activated 
satellite cells differentiate into a quiescent state, with a cocurrent increase of Pax7 expression (Fig. 5 and 6). 
In vivo, this would represent a mechanism for satellite cells to maintain a reserve of myogenic progenitor cells 
(quiescent satellite cells, or reserve cells). The oxygen concentration during culture of human satellite cells is 
not a significant regulating factor in differentiation. However, low oxygen concentration does promote PAX7 
expression, engaging satellite cells in myogenic lineage and promoting more efficient proliferation.
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or dedifferentiate towards their quiescent state (Fig. 8). We surmise that this in vitro 
synchronous bi-directional differentiation of satellite cells reiterates in vivo proces-
ses in which an appropriate niche of myogenic progenitor cells (quiescent satellite 
cells, or reserve cells [89]) is recreated upon regeneration of ischemic muscle tissue. 
Furthermore, this is in concordance with the findings derived from mice and rat tissue, 
that satellite cells can both self-renew and differentiate after transplantation [83,165]. 
Moreover, this process could be influenced by various signaling pathways promo-
ting either myoblast and myotube formation or quiescent satellite cells [166-171]. 
This offers great potential for future clinical applications of tissue engineered mus-
cle, where the presence of cells with a self renewing capacity is essential. Moreover, 
we find that these processes are not influenced by hypoxia, which satellite cells will 
encounter upon implantation.
For tissue engineering, where large cell numbers are required, hypoxia improves 
proliferation during low passage tremendously. We therefore recommend culturing 
human satellite cells under hypoxic conditions during the first passages.
CONCLUSION
Hypoxic culture conditions promote initial cell proliferation of human satellite cells. 
Moreover, while satellite cells differentiate into myotubes, they maintain a pool of 
quiescent satellite cells with qualities which are unaffected by hypoxia. Combined, 
this renders human satellite cells highly suitable for tissue engineering of skeletal 
muscle for future clinical application.
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Innovative strategies such as tissue engineering of skeletal muscle constructs are pro-
mising for treatment of patients with skeletal muscle damage. How these human mus-
cle constructs differentiate into mature muscle fibers in vivo remains to be elucidated. 
Therefore, we engineered 3D muscle constructs in collagen type I gels with clonally 
expanded human satellite cells. These constructs were preconditioned in vitro with 
10 % human umbilical vein endothelial cells (HUVEC) for 5 days to investigate the 
effect on vascularisation in vivo.
Engineered constructs were implanted subcutaneously in nude rats for 1, 5, 10 or 
21 days. After explantation, morphological analysis revealed progressive and exten-
sive mature muscle fiber formation. Irrespective of the in vitro preconditioning with 
HUVEC, functional vascularisation was host-derived and equally efficient in both 
types of constructs.  Analyses of myogenic regulator factors showed that muscle fiber 
formation and maturation occurred from the periphery of the construct inward. Trans-
mission electron microscopy and qRT-PCR confirmed the formation of mature ske-
letal muscle during the 21 day time course.
In conclusion, this study shows advanced skeletal muscle fiber formation by human 
satellite cells in vivo. Most importantly, we show that the formation and engraftment 
of human skeletal muscle in vivo is independent of preconditioning with HUVEC in 
vitro. Tissue engineering of human skeletal muscle without the need of in vitro prevas-
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INTRODUCTION
Tissue engineering of autologous skeletal muscle aims to develop an improved treat-
ment for patients with muscular deficiencies such as in facial paralysis. In this condi-
tion paralyzed facial muscles impair facial expression and cause significant physical, 
psychological and social distress. Surgical reconstructive options are available but 
slim because there are no autologous donor muscles with the same characteristics as 
these small facial muscles, and genuine regeneration is not achieved [6,7]. Engineered 
skeletal muscle tissue on the other hand, may be customized and offers an opportunity 
for patients to obtain a more natural result, without causing donor site morbidity [44] 
or downsides of current free flap reconstructions such as undue swelling or even the 
autostatic syndrome [5].
Muscle tissue has an endogenous repair mechanism through myogenic progenitor 
cells, i.e. satellite cells. Upon stimulation such as damage, satellite cells proliferate 
and differentiate into myotubes and muscle fibers, to regenerate the damaged mus-
cle [82-85,172]. These regenerative capacities of human satellite cells make them a 
suitable source for muscle tissue engineering [91,130].
However, for successful regeneration of functional muscle tissue that exceeds the 
thickness compatible with nutrition by diffusion, a vascular network is required to 
exchange oxygen and nutrients. If revascularisation of large muscle grafts, either 
transplanted or engineered, proceeds too slow for effective regeneration to occur, this 
leads to fibrosis and loss of tissue [173]. Even though satellite cells are resilient to 
hypoxic conditions [112], and facial muscles are relatively thin and small compared 
to other skeletal muscles, vasculature will be imperative for sustainability and growth 
of the muscle tissue. 
 Endothelial cells form vascular like structures in vitro, a process which is enhanced 
by co-culture with mesenchymal stem cells such as adipose derived stem cells or bone 
marrow derived stem cells [174,175], cardiomyocytes [176] or myoblasts [177,178]. 
Also when implanted subcutaneously, co-cultures of endothelial cells with mesenchy-
mal stem cells or myoblasts improved blood perfusion and survival in vivo [179,180]. 
However, these studies mainly focus on endothelial cells and vascularisation, and in 
those that do implement satellite cells, the formation of skeletal muscle is underex-
posed. 
A 3D muscle construct developed with collagen type I (ColI) gel offers an environ-
ment with extracellular matrix and may resemble the architecture of the cells natural 
niche in vitro. An advantage of this ColI construct is that it can be molded into shape, 
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cells can be seeded uniformly and it promotes cellular organization. Subsequent strain 
that cells experience during in vitro culture in this ColI construct, promoted the alig-
nment of the murine cell line C2C12 and the endothelial cell line H5V [144]. Also 
cardiomyocytes that were cultured in this 3D ColI construct experience strain that 
promoted aligned architecture in vitro [181]. Although cell lines, cardiomyocytes and 
other animal derived cells shed light on general mechanisms such as differentiation 
and alignment, these cells do not exactly represent human satellite cells in vitro nor 
in vivo [147,182]. 
We engineered 3D skeletal muscle constructs in vitro with clonally expanded human 
satellite cells to investigate differentiation of satellite cells and myotubes, and sub-
sequent muscle fiber formation in vivo. Furthermore, we investigated the effect of in 
vitro preconditioning of these muscle constructs with human umbilical vein endothe-
lial cells (HUVEC) on muscle fiber formation and vascularisation in vivo. 
MATERIALS AND METHODS
Satellite cell isolation and culture
A muscle biopsy was obtained from a 60 year old healthy female, undergoing blepha-
roplasty. The study protocol was approved by the institutional medical ethics commit-
tee, and the donor gave her informed consent. Satellite cells were isolated after enzy-
matically dissociation of the muscle biopsy. Dissociation was performed with 0.04 
mg/ ml (0.16 Collagenase Wünsch units/ml) Liberase Blendzyme 3 (Roche Applied 
Science, the Netherlands). Satellite cells were proliferated with proliferation medium 
(PM) which consisted of Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen/
Gibco, CA, USA), 20 % Fetal Bovine Serum (FBS; Invitrogen/Gibco) and 1 % peni-
cillin/streptomycin 50 μg/ml (Sigma-Aldrich, St. Louis, USA). 
Differentiation medium (DM), contained DMEM, 2 % FBS, 1 % penicillin/strepto-
mycin, 1 % Insulin-Transferrin-Selenium-A (100x) (Invitrogen) and 0.4 μg/ml dexa-
methason (Sigma-Aldrich). Medium was refreshed every other day. Cells were plated 
at 5.0 x 103 cells/cm2 in culture flasks precoated with 1 % gelatine/PBS for 30 min. 
When cells reached 70 % confluence they were enzymatically harvested using Accu-
tase (Invitrogen) and passaged.
Passage number (Px) was defined as the xth sequential harvest of a subconfluent cell 
population. At passage 8, cells were cloned by sorting single cells in 96 wells plates 
using a MoFlow FACS. A clone that uniformly expressed the satellite cell marker 
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Pax7 and the myogenic regulator factors MyoD and Myogenin was selected for all 
experiments. 
Human umbilical cord endothelial cells (HUVEC) were obtained through Prof. Dr. G. 
Molema (Dept. Pathology and Medical Biology, UMC Groningen, The Netherlands). 
HUVEC were cultured in gelatin-coated culture flasks in endothelial cell medium 
(ECM) until they reached confluence. ECM comprised of RPMI 1640 (Cambrex, NJ) 
supplemented with 20 % FBS, 2 mM L-glutamine (Sigma, St. Louis, MO), 1 % peni-
cillin/streptomycin, 5 U/mL heparin (Leo Pharma, The Netherlands) and 5 mg/mL 
endothelial cell growth factors (ECGF; own isolate according to Burgess et al [183]). 
HUVEC cultures typically contained > 98 % cells expressing endothelial markers 
including VE-Cadherin and CD31, while sprouting networks formed within 6 hours 
on Matrigel® (BD Biosciences).
3D muscle construct engineering
Muscle constructs were cultured as previously described [105]. Briefly, house-shaped 
pieces of Velcro were glued to the bottom of a 6 wells plate 12 mm apart, sterilized 
with ethanol (70 %) and subsequent exposed to UV for 15 min. A gel mixture was 
prepared on ice by mixing 50 % Collagen type I (3,44 mg/ml, BD Biosciences), 39 % 
PM, 3 % 0.5 M NaOH (Sigma-Aldrich), 8 % growth factor reduced Matrigel. Three 
groups were cultured: a bare construct without cells, a construct with satellite cells, 
a construct with a mixture of satellite cells and HUVEC. Cells were harvested and 
mixed with the gel at a concentration of 4.5 x 106 per ml satellite cells and 4.5 x 105 
per ml HUVEC. Then, 350 µl of gel mixture was pipetted in and between the Velcro 
anchoring points. After 1 hour gelation, 3 ml PM was added which was replaced after 
24 hours with DM, and refreshed daily for 5 days at which point the implantation in 
rats was performed.
Animal experiments
Male, athymic nude rats (Harlan, the Netherlands), 6 weeks of age, were held under 
specific pathogen-free conditions in individual ventilated cages and received food and 
water ad libitum. Animal experimentation was approved by the local Ethical Commit-
tee on Animal Experiments (DEC5729) and was conducted according to governmen-
tal and institutional guidelines on animal experimentation.
Rats were anesthetized with a mixture of isofluorane (Forene/Abbott BV, the Nether-
lands) and oxygen, and received 0,01 mg/kg Temgesic sc. per-operative. The back 
was disinfected and subcutaneous pockets were made to the left or right flank through 
82
CHAPTER 6
5 mm incisions. The constructs were implanted 1cm from the site of incision. Inci-
sions were closed with a 5.0 Viclyl suture (Ethicon, VWR International). At day 1, 
5, 10 or 21 after implantation, rats were anesthetized and the muscle constructs were 
explanted along with sample surrounding tissue (N = 6 per time point). The explants 
were fixed in either 2 % glutaraldehyde (in 0.1 M sodium phosphate buffer), 10 % 
formaldehyde or liquid nitrogen for further tissue processing.
Immunofluorescent staining 
For histochemical analyses, glutaraldehyde-fixed explants were dehydrated, resin 
(Technovit 7100, Heraeus Kulzer, Germay) embedded, sectioned at 2 μm and stained 
using toluidine blue according to standard procedures. Toluidine blue-stained sections 
were randomized and evaluated for cellular density.
For immunohistochemical analysis, sarcomere components were detected with mouse-
anti-human α-sarcomeric actin (1:100) (Sigma-Aldrich), mouse-anti-human myosin 
(MF20; 1:500) (Developmental Studies Hybridoma Bank, Iowa, USA (DSHB)) and 
rabbit-anti-human Desmin (1:100) (Novus Biological, Littleton, USA) in 4 μm sec-
tions which were prepared from paraffin-embedded explants, deparaffinized before 
staining.
Myogenic transcription factors were detected with mouse-anti-human MyoD (1:100) 
(Dako, Glostrup, Denmark), mouse-anti-human Myogenin (F5D; 1:500) (DSHB) and 
mouse-anti-human Pax7 (1:10) (DSHB). And endothelium was detected with mouse-
anti-rat His52, and mouse-anti-human CD31 (1:100) (Dako) in 4 μm sections prepared 
from frozen explants. After three washes with 0.05 % Tween in PBS, sections were 
incubated with a secondary antibody-cocktail constituted of FITC-conjugated goat-
anti-rabbit IgG (1:100) (Southern Biotech, AL, USA), and Alexa Fluor®555 goat-
anti-mouse IgG1 or IgG2b (1:300) (all Invitrogen) and 10 % normal human serum 
in PBS/DAPI. Sections were mounted in Citifluor AP1 (Agar Scientific, Essex, UK).
Three images of each type of construct of day 5, 10 and 21 were analyzed for the 
orientation of the cells in the constructs with an in-house algorithm as previously 
described [144]. In short, for each pixel, the probability that it belongs to a structure 
was calculated, followed by an estimation of structure orientation. The algorithm was 
implemented in Mathematica (Wolfram). The orientation was plotted in a histogram.
Gene transcript analysis
Total RNA was isolated from frozen samples using the RNeasy Kit (Qiagen Inc., CA, 
USA), in accordance to the manufacturers protocol. Briefly, cells were lysed and dilu-
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ted with an equal volume of ethanol (70 %). RNA was collected on an RNA binding 
filter by centrifugation. DNA was removed by incubation with a DNase I solution at 
37 °C for 15 min. The RNA-binding filter was washed twice and subsequently the 
RNA was eluted with 14 μl Elution Buffer. The RNA concentration and purity were 
determined by spectrophotometry (NanoDrop Technologies, Wilmington, NC). For 
qRT-PCR analysis, total RNA was reverse transcribed using the First Strand cDNA 
synthesis kit (Fermentas UAB, Lithuania). In summary, 1 μg of total RNA was diluted 
in a final reaction volume of 20 μl containing random hexamer primer (0.5 μg), Ribo-
Lock™ Ribonuclease Inhibitor (20 U), 1 mM dNTP mix, and incubated at 37 °C for 
1 h. The reverse transcription reaction was terminated by heating the mixture to 70 °C 
for 10 min, after which the samples were placed on ice. Quantitative RT-PCR analysis 
was performed in a final reaction volume of 10 μl, consisting of SYBR Green Super-
mix (Bio-Rad, Hercules, USA), 0.5 mM primer-mix (Table 1) and 5 ng cDNA. Reac-
tions were performed at 95 °C for 15 s, 60 °C for 30 s, 72 °C for 30 s, for 40 cycles. All 
human sequences were confirmed unique and non crossreactive by BLASTn analysis. 
Data were analyzed using Science Detection Software 2.2.2. To determine differences 
in expression, Ct-values were normalized against GAPDH-expression using the ΔCt-
method (ΔCt(gene) = Ct(gene) – Ct(GAPDH)). Fold change was calculated against the ΔCt of 
SC explants at day 1. All cDNA samples were amplified in triplicate, and 3 separate 
constructs per construct type were used.










All data are represented as mean ± SEM and statistical comparison between two 
groups was performed using the Student’s t test. When comparing more than two 
groups one way ANOVA was used followed by the post hoc Bonferroni’s multiple 
comparison test in Graph-Pad Prism Version 5 (GraphPad Software, Inc., La Jolla, 




In vitro tissue engineering of a three dimensional muscle construct 
Human satellite cells were isolated and cultured from enzymatically dissociated mus-
cle tissue. Initial passages comprised of heterogeneous cell populations. To obtain a 
pure satellite cell population for in vivo experiments, cells were cloned and individual 
clones expanded; the fraction of human satellite cells that was able to clonally expand 
was 26.3 ± 4.0 %. A clone that uniformly expressed the satellite cell marker Pax7 and 
the myogenic regulator factors MyoD and Myogenin was selected for all experiments. 
Satellite cells differentiated in vitro in a collagen type I (ColI) gel and a three dimen-
sional construct developed within 5 days (Fig. 1A). In both types of constructs, with 
or without HUVEC (10 satellite cells : 1 HUVEC), myotube formation was observed. 
The myotubes aligned parallel to the constraining direction (Fig. 1A-B, arrowheads). 
Double staining for desmin and myogenin showed a homogenic distribution of satel-
lite cells and myotubes throughout the gel. The nuclei of these myotubes were still 
centrally located. The myogenin expression shows the pre-disposition of myotubes 
and mononuclear cells for muscle formation (Fig. 1B). 
In vivo development of a muscle construct 
The in vitro engineered muscle constructs, developed by mixing ColI with either 
human satellite cells alone or satellite cells and HUVEC, were evaluated after sub-
Figure 1. A tissue engineered muscle construct in vitro. (A) After 5 days of culture, the muscle construct 
consists of a compact gel between two fixed velcro points (arrowheads) approximately 120 mm apart. (B) 
An immunofluorescent image of a muscle construct shows that satellite cells and myotubes express Desmin 
(green) and Myogenin (red). Nuclei are counterstained with DAPI (blue). Scalebar is 200 µm.
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cutaneous implantation in athymic nude rats. At all timepoints HUVEC were present 
in the explants of the HUVEC loaded muscle constructs (Fig. 2). After 1 day, the cell 
membrane and nucleus of most satellite cells within the implanted construct were 
sharply defined, indicating viability (Fig. 4A-B). Cells displayed the same healthy 
morphology in both types of constructs. After 5 days, myotubes had clearly widened, 
elongated and clustered (Fig. 4C-D). This process continued and at day 10, the num-
ber, diameter and length of myotubes had further increased in both types of constructs. 
Though myotubes were located predominantly at the outer layer of the constructs, at 
this time point they also started to appear in the center. In the bare implanted ColI 
gels, cellular infiltration was sporadically observed (Fig. 3), while in the cell-loaded 
gels, the ratio between cells and ColI gel had shifted and mostly cells and myotubes 
are seen (Fig. 4E-F). The development of muscle tissue continued and at day 21 the 
myotubes present throughout the constructs were striated and had flattened nuclei 
close to the sarcolemma (Fig. 4G-H). 
Functional vascularisation of muscle constructs in vivo
We investigated the influence of preconditioning with or without HUVEC in vitro 
on the vascularisation of muscle constructs in vivo. At macroscopic level, the muscle 
constructs had compacted from 120 mm long by 0.5 mm thin structures to round sha-
ped structures approximately 5 mm in diameter. Vascularisation of the constructs was 
comparable to the surrounding tissue. At microscopic level, the outer layers of both 
types of constructs were vascularised after 5 days (Fig. 4D.1), while in bare constructs 
vascularisation was virtually absent (Fig. 3). At day 10 and 21 vascularisation had 
further developed with increased numbers of vessels present throughout the construct 
and also in-growth of large vessels (Fig. 4E). These neovessels originated from the 
Figure 2. Immunofluorescent staining for CD31 (red) of explanted collagen I muscle constructs preconditioned 
with HUVEC at (A) day 1 and (B) day 21 after implantation. Nuclei were counterstained with DAPI (blue). Sca-
lebars are 100 µm.
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Figure 3. Toluidine blue staining of cross sections of explanted bare collagen I constructs. Note that there is 
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Figure 4. Development of a muscle construct after subcutaneous implantation. Toluidine blue staining of 
cross sections of muscle constructs (A, C, E, G) with human satellite cells alone or (B, D, F, H) with satellite 
cells and HUVEC. At day 1 (A, B), satellite cells and myotubes have round morphology (A.1). At day 5 (C, D), 
myotubes elongate, and in both types of constructs, with or without HUVEC, small vessels (V) appear in the 
outer layers (D.1). At day 10 (E, F), elongated thick muscle fibers form, and large vessels invade both types of 
constructs (F.1). At day 21 (G, H), muscle fibers display cross-striations, and vessels are present throughout the 
whole construct. (G.1) Erythrocytes are seen in the vessels. Scalebars are 100 µm.
host vasculature, and were functional as indicated by the presence of erythrocytes in 
the lumen. Furthermore, some of the large vessels aligned with the formed muscle 
fibers (Fig. 4G.1). 
Immunostaining for rat endothelial cells showed ingrowth of rat derived vasculature 
in the muscle construct at day 5 (Fig. 5A). This host-derived vascularisation occurred 
in constructs with and without HUVEC equally (Fig. 5B, C). At day 21, host-derived 
vessels had fully aligned with the human muscle fibers (Fig. 5D). Transmission elec-
tron microscopic (TEM) analysis also showed the integration of functional vessels in 
between muscle fibers (Fig. 5E). To investigate the stimulus for angiogenesis we ana-
lyzed quantitative gene expression of VEGF that was produced in both types of mus-
cle constructs. This showed that at day 1 VEGF production was 8.4 ± 4.5 fold higher 
in constructs with HUVEC. However, the differences were not significant (Fig. 5F).  
Skeletal muscle fiber formation by human satellite cells in vivo
TEM was employed to examine the ultrastructure of the muscle fibers that had formed 
in the constructs. We observed that myotubes formed mature muscle fibers that con-
sisted of several tightly aligned myofibrils (Fig. 6A). The aligned myofibrils resulted 
in a cross-banded appearance which is typical for adult skeletal muscle. The dark 
A-bands were of constant length and contained a less dense central zone, the H-band, 
which was marked in the middle by the M-line. The I-band (which is known to con-
sist of actin filaments) was bisected by a dense Z-line, where the filaments were joint 
laterally. Mitochondria were arranged in longitudinal direction between myofibrils, 
or still scattered throughout less mature muscle fibers. Nuclei had an open chromatin 
structure and the cytoplasm was well developed, which reflects a high activity in these 
cells. The myotube fusion process into muscle fibers was confirmed by TEM analysis 
too (Fig. 6B).
During in vivo development of the muscle construct, we found that myotubes werelo-
cated predominantly at the outer layer of the construct. The surface of this outer layer 
increased compared to the total surface of a construct when measured in a cross section. 
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After 5 days, 5.2 ± 3.7 % of the total surface of satellite cell only constructs consisted of 
a layer of myotubes. After 21 days, this layer increased to 51.3 ± 1.5 % of the total cross 
sectional surface area. In constructs with HUVEC added, after 5 days, this layer was 
18.1 ± 1.8 %, while after 21 days, this layer increased to 33.9 ± 1.6 % of the total surface. 
This increase however, was less than in satellite cell only constructs (p = < 0.01; Fig. 6C).
Myogenic regulator factors in human satellite cells promote differentia-
tion in vivo
At all timepoints the satellite cell marker Pax7 was present throughout both types of 
muscle constructs (Fig. 7A-B). In general, both myogenic regulator factors myogenin 
and MyoD were predominantly expressed by satellite cells and myotubes located in 
the outer layer and at places where curvature of the construct was most pronounced. 
At day 21, myotubes that expressed myogenin were present throughout the construct. 
This was comparable for both types of constructs. Myotubes that had fused into 
mature muscle fibers, showed a decreased expression of myogenin, as well as flat-
Figure 5. Functional vascularisation of muscle constructs in vivo. (A-D) Immunofluorescent staining for rat 
endothelial cells (RECA; red) and human muscle cells (desmin; green), nuclei were counterstained with DAPI 
(blue). (A) Day 5 showed ingrowth of rat derived vasculature in the muscle construct. (B, C) Day 21 showed rat 
derived vasculature throughout both types of muscle constructs. (D) Detail of a vessel wrapped around a mus-
cle fiber. (E) TEM shows a vessel located between three adjacent muscle fibers in cross section. Erythrocytes 
are present in the lumen. Scalebars are 200 µm, 50 µm and 10 µm respectively. (F) VEGF production at gene 
expression level. (N = 3; data are represented as means ± SEM).
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tened nuclei on the outer layer of the fiber (Fig. 7C). Maturation of muscle fibers was 
most pronounced in the outer layer of the muscle constructs. At day 21, satellite cells 
and myotubes that expressed MyoD were present throughout both types of muscle 
constructs (Fig. 7D).
The increased expression of myogenic regulator factors by satellite cells and myotu-
bes, was followed by mature muscle fiber formation and a subsequent increase in the 
expression of maturation markers such as desmin, α-sarcomeric actin and myosin. 
Moreover, these myotubes had aligned, which increased during in vivo maturation 
at the edge of the constructs (Fig. 7E boxed areas; E.1). Both quiescent satellite cell 
maintenance as muscle fiber development and alignment, were not influenced by the 
preconditioning with HUVEC. 
This was largely confirmed by quantitative gene expression analysis of explanted mus-
cle constructs. The satellite cell marker PAX7, the myogenic regulator factor MYOD1 
and genes of myogenic differentiation DES, ACTA1, MYL1 and MYL3 were upregula-
ted during maturation in vivo. For all genes but MYL1, this upregulation was similar in 
constructs with HUVEC (Fig. 8). Therefore, also at gene expression level, myogenic 
regulator factors and mature muscle markers showed muscle fiber formation.
Figure 6. Skeletal muscle fiber formation by human 
satellite cells in vivo. (A) A Transmission Electron 
Microscopic image showed muscle fibers that consisted 
of several myofibrils in a longitudinal section. The dark 
A-bands contained a less dense central zone, the H-zone, 
in the middle marked by the M-line. The I-band was bisec-
ted by a dense Z-disk. Mitochondria* were arranged in 
longitudinal direction between myofibrils. (B) Mitochondria 
were scattered throughout less mature muscle fibers in 
fusion with one another (arrowheads). Scalebars are 10 µm. (C) The surface of myotubes and muscle fibers 
was compared to the total surface of a construct measured in a cross section (N = 3; data are represented as 
means ± SEM; * p = < 0.01).
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Figure 7. Myogenic regulator factors in human satellite cells promote differentiation in vivo. (A-B) Cross 
sections of muscle constructs with (B) or without (A) HUVEC, stained for Desmin (green) and Pax7 (red) at 
day 21. (C) Immunofluorescent staining of Desmin (green) and Myogenin (red) at day 21 showed terminally 
differentiated muscle fibers. (D) Immunofluorescent staining of Desmin (green) and MyoD (red) at day 21. (E) 
Immunofluorescent staining of Desmin (green) and Myogenin (red) at day 5, 10 and 21. The boxed area is 
quantified in E.1, where the number of pixels with a certain degree angle shows the alignment of myotubes and 
muscle fibers with each other. Nuclei were counterstained with DAPI (blue). Scalebars are 100 µm.
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DISCUSSION
The current study set out to investigate the differentiation of clonally expanded human 
satellite cells and myotubes and subsequent muscle fiber formation subcutaneously in 
nude rats. In vivo, we showed that these satellite cells, after in vitro preconditioning in 
a 3D ColI gel, differentiate to form mature muscle fibers and quiescent satellite cells. 
A major finding was that the vascularisation of the mature human muscle fibers was 
host-derived vasculature. Furthermore, vascularisation immediately occurred upon 
implantation and proceeded along with maturation of the muscle constructs. Remar-
kably, in vitro preconditioning of the ColI muscle construct with HUVEC did not alter 
vascularisation, nor did it alter the differentiation of satellite cells or the muscle fiber 
formation in vivo. 
Differentiation of satellite cells and myotubes into mature muscle fibers started at the 
outer layer of a muscle construct and then progressed inward (Fig. 4). Importantly, 
this muscle fiber formation was preceded by an upregulation in the myogenic regu-
lator factors such as myogenin (Fig. 7C; E) and MyoD (Fig. 7D). At day 1, 5 and 10, 
the expression was predominantly located in the outer layers of the muscle construct, 
while at day 21 also centrally in the muscle construct cells expressed the myogenic 
regulator factors. The course of the muscle fiber formation could be explained in two 
ways. Firstly, the initiation and formation of myotubes during the in vitro preconditi-
oning is likely promoted by the tension experienced by the satellite cells and myotu-
bes in a muscle construct [144,181]. In addition, the expression pattern of myogenic 
regulator factors indicates that also in vivo, the increased tension that satellite cells 
and myotubes experience in the outer layers of the muscle construct, promotes muscle 
fiber formation. Interestingly, tension was also found to promote alignment of the 
murine cell line C2C12 [29]. We showed that also mature human muscle fibers align 
with each other (Fig. 6B). 
Secondly, the in vivo formation of muscle fibers may be affected or depend on the 
coinciding vascularisation of the newly formed fibers [177]. This is supported by our 
observation that the outer layers are vascularised first by the host, they are therefore 
oxygenated earlier than the center of the construct. This contributes to muscle fiber 
formation [155]. Mononuclear satellite cells on the other hand are very resilient to 
hypoxic environments, they proliferate or become quiescent while maintaining their 
myogenic regenerative capacity (Fig. 7A) [112,158]. 
We choose to precondition muscle constructs with HUVEC in vitro, since endothelial 
cells contribute to neovascularisation through paracrine signaling [184]. Remarkably, 
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our results show that in vitro preconditioning of a muscle construct with HUVEC, 
did not improve vascularisation in vivo. Also muscle differentiation was not affec-
ted by the presence of HUVEC at 21 days. This suggests a higher self-reliance of 
human satellite cells compared to C2C12, as C2C12 do benefit from preconditioning 
in vitro for muscle fiber formation [144] and in vivo integration [25,179]. Interes-
tingly, we found that only during the first 5 days after implantation preconditioning 
with HUVEC did ameliorate muscle fiber formation in vivo (Fig. 4C; D). After this, 
the difference in muscle fiber formation was even surpassed in the non-preconditioned 
muscle constructs. The initial head start might be a result of slightly increased VEGF 
production at day 1 by muscle constructs preconditioned with HUVEC (Fig. 5F). 
It is suggested that VEGF enhances myotube formation in vitro [185,186]. Also in 
vivo, it is suggested that VEGF enhances myotube formation [187,188] and engraft-
ment of human myoblasts in mouse muscles [155]. However, during differentiation 
of satellite cells, VEGF production by satellite cells is upregulated [185]. Hence, our 
results indicate that VEGF from differentiating satellite cells regulates rat endothelial 
cell recruitment and vascularisation sufficiently [173,177,189-191]. Taken together, 
we show that in vitro preconditioning with HUVEC might be redundant in tissue 
engineering of small skeletal muscle tissue. The relatively thin and small facial mus-
cles especially are a good model for the non-preconditioned muscle constructs. Lar-
ger skeletal muscles might still dependent on pre-vascularisation for their survival.
Figure 8. Quantitative gene expression analysis of explanted muscle constructs. (N = 3; data are represented 
as means ± SEM).
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CONCLUSION
This study uniquely shows in vivo formation of mature muscle fibers and quiescent 
satellite cells by human satellite cells applied in an in vitro engineered muscle con-
struct. Most importantly, we show that the formation and survival of mature human 
muscle is independent of preconditioning with HUVEC. Therefore, though innerva-
tion is a hurdle that remains to be addressed, this approach for tissue engineering of 










Tissue engineering as a treatment option for longstanding facial para-
lysis
Significant loss of functional muscle tissue has a profound impact on a patient’s life 
due to the limited capacity of self-repair of the muscle. Especially patients with long-
standing facial paralysis suffer from a complex trilogy of physical, social and psy-
chological symptoms. In a world where millions are spent on appearance, an asym-
metric, paralyzed face causes severe psychological stress and even depression in some 
patients. It is estimated that every year approximately 4,000 people in the Netherlands 
are struck by facial paralysis. A large proportion of them recover spontaneously. Yet 
about 1,200 patients have persisting signs and symptoms. There are major advance-
ments in the field of reconstructive surgery, and conservative, non-surgical treatment 
strategies [12]. However, only seldom can the asymmetry of the face be restored com-
pletely [10]. For these patients new, innovative treatment strategies need to be develo-
ped. The generation of skeletal muscle tissue using tissue engineering methods holds 
promise for the future treatment of these patients. Therefore, the main objective of this 
thesis was to improve tissue engineering of human skeletal muscle. We argued that 
new insights to promote and control tissue engineering of human skeletal muscle can 
be gained by studying human muscle progenitor cells, i.e. satellite cells, during their 
differentiation in vitro and in vivo.
Human satellite cells for tissue engineering of skeletal muscle 
Skeletal muscle comprises of a mixture of both slow and fast twitching fibers, respec-
tively myosin type I and type II. Facial muscles consist predominantly of fast type 
myosin [192,193].The differences between muscle fiber type also appear to be reflec-
ted in satellite cells. Their phenotype reflects the myosin type of the fiber of origin 
[194] (chapter 2). In this thesis we describe that human satellite cells clonally expand 
and have a relative fast proliferation rate in vitro (chapter 3, 5), thus theoretically, a 
single human satellite cell is sufficient to tissue engineer skeletal muscle for clinical 
application. Hence, only a small muscle biopsy is required to isolate satellite cells 
that are needed. We found that the part of the orbicularis oculi muscle that is removed 
during an upper eyelid blepharoplasty, is a sufficient source of satellite cells for tissue 
engineering purposes, and has virtually no donorsite morbidity. 
This thesis shows fundamental regulatory processes of human satellite cells. We sho-
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wed that, during in vitro differentiation of these cells, part of the population fuses 
and forms myotubes, while simultaneously another part returns to a quiescent state. 
Both processes are vital in tissue engineering: myotubes are required to form muscle 
fibers for contractility and force generation. And quiescent satellite cells are required 
to maintain their regenerative capacity, i.e. maintain the progenitor cell pool in engi-
neered muscle. 
Currently, two main theories that exist on the differentiation process of satellite cells: 
The first theory is that quiescent satellite cells undergo either symmetric cell division 
to maintain the progenitor cell pool or asymmetric cell division to contribute to mus-
cle fiber repair [91]. This means that, when muscles are injured, quiescent satellite 
cells first proliferate and then either terminally differentiate into myotubes or dedif-
ferentiate to replenish the quiescent satellite cell pool (Fig. 1A). The second theory is 
that upon damage, quiescent satellite cells are activated and start proliferating. These 
proliferating satellite cells then differentiate to terminal differentiated myotubes and 
quiescent satellite cells [146]. This means that, when muscles are injured, quiescent 
satellite cells go through an activated, proliferative stage. From this transitory proli-
ferating population, most satellite cells undergo terminal differentiation while a few 
return to a stage to renew the quiescent satellite cell pool (Fig. 1B). Our findings, that 
a homogeneous clonally expanded cell population forms two different cell populati-
ons distinct from the original population (chapters 3 and 6), support the second theory.
MicroRNAs as a tool to tip the balance in favor of myotube formation
MicroRNAs have widely been accepted to play a role in tipping the balance in regu-
latory processes of various cell types. But as a tool to enhance (skeletal muscle) tissue 
engineering, microRNAs are a relative new concept. It was shown that by inhibi-
tion microRNA-133a in a murine myoblastic cell line C2C12, myotube formation 
was enhanced [143]. In chapter 3 of this thesis we showed that microRNAs are not 
involved in human quiescent satellite cell formation. However, in myotube forma-
tion both microRNA-1 and microRNA-206 are strongly upregulated. By further pro-
moting these microRNAs in proliferating satellite cells even further (chapter 4), we 
tipped the balance and enhanced the potential for myotube formation. Also in a 3D 
muscle construct engineered from human satellite cells and collagen I gel, microRNA 
promotion enhanced myotube formation. This can become an important tool in tissue 
engineering. Especially with respect to aging, because with increasing age, the popu-
lation of satellite cells per myofiber decreases [131,132]. Moreover, it has been shown 




This implies that tissue engineering of skeletal muscle from autologous satellite cells 
from aged patients can be impaired. Furthermore, the efficiency of tissue engineering 
of skeletal muscle will vary between individual patients [135,136]. Overall, modula-
ting satellite cell differentiation by promoting microRNAs might offer opportunities 
in enhancing the efficacy of successful tissue engineering of human skeletal muscle.
In vivo maturation of a tissue engineered human skeletal muscle con-
struct
Upon clinical application, i.e. implantation of the engineered collagen I muscle 
Figure 1. Two current models explaining the self-renewal and differentiation of satellite cells in mus-
cles. (A) In a first model, Pax7pos satellite cells co-exist with ‘committed’ satellite cells. Pax7pos cells undergo 
symmetric cell division to amplify or maintain, respectively, the stem cell pool, while ‘committed’ satellite cells 
undergo asymmetric and terminal differentiation. (B) In a second model, quiescent (Pax7pos) satellite cells go 
through an activated, proliferative stage. From this transitory proliferating population, most cells form myotubes 




constructs, human satellite cells will encounter changes in oxygen level. How this 
will affect human satellite cell survival, proliferation and differentiation is largely 
unknown. In primary rat or bovine satellite cells hypoxic conditions promote myotube 
formation [158,163]. This is in contrast to C2C12 cells in which myotube formation 
is delayed due to a downregulation of MYOD1 [164]. Chapter 5 reveals that hypoxic 
culture conditions enhanced proliferation of human satellite cells, without affecting 
their differentiation capacities. This is also an inspiring finding for in vivo applications 
of human satellite cells. Therefore, in chapter 6 we investigated differentiation and 
maturation of clonal human satellite cells in a 3D collagen I muscle construct implan-
ted subcutaneously in nude rats. Subcutaneous implantation is a representative model 
for future application in patients with longstanding facial paralysis since in facial 
paralysis there is not a muscle defect but completely lacking muscle tissue. 
It has been shown in vitro that in this type collagen I construct, C2C12 cells form 
myotubes that align parallel to the constraining direction [144]. We demonstrate sub-
cutaneously in nude rats that clonal human satellite cells in collagen I constructs for-
med both aligned mature muscle fibers and quiescent satellite cells. Moreover, we 
showed that the muscle fibers were spontaneously and functionally vascularised by 
the host vasculature. This was in contrast to the bare collagen I gel, that showed no 
cellular infiltration or vessel formation, and served as an inert scaffold.
Levenberg et al. showed in nude mice that vascularisation of a C2C12 con-
struct is promoted by human endothelial cells [25,179]. However, we found that 
host vascularisation of human muscle fibers was not promoted by the addition of 
human endothelial cells. Furthermore, Levenberg et al. also showed that vascula-
Figure 2. A Transmission 
Electron Microscopic 
image showed extracel-
lular matrix formation in 
the human satellite cell 
muscle construct, and 
decreased muscle fiber 
formation after 21 days in 




risation was promoted by additional support of embryonic human fibroblasts [25].
Yet in our hands (not shown in this thesis), the addition of supporting human adi-
pose derived stem cells in vivo, only caused extracellular matrix formation in the 
muscle construct, and resulted in a decreased muscle fiber formation (Fig. 2). 
Taken together, the results of this thesis show that the murine myoblast cell line 
C2C12 greatly differs from primary human satellite cells. The translation from regu-
latory mechanisms in satellite cells to clinical application depends on the use and 
investigation of human satellite cells specifically in our view. Furthermore, we can 
conclude that clonal human satellite cells applied in a 3D collagen I gel is currently 
the optimal approach for tissue engineering of small human skeletal muscles. This 
offers potential for the treatment of small, thin facial muscles in patients with long-
standing facial paralysis.
FUTURE PERSPECTIVES
In this thesis we showed that cloned human satellite cells in a collagen I construct 
form well vascularised mature muscle tissue after subcutaneous implantation in rats. 
However, various steps still have to be made to reach clinical application of such 
human muscle constructs. 
To start, a more thorough analysis of human facial muscle characteristics could be 
performed to determine what prerequisites a tissue engineered muscle construct needs 
to meet. This means that the minimal contraction force that a construct should deliver 
and accurate size measurements of the different facial muscles have to be documen-
ted. 
Through anatomical dissection and MRI investigation a general, but accurate picture 
of human facial muscles can be established. These studies will give a framework for 
the characteristics of facial muscles. Based on this framework, a combination of rapid 
prototyping, like 3D printing [195,196], and tissue engineering will hold promise for 
facial muscle repair in the individual patient.  
Furthermore, though in our study human myotubes matured and formed muscle fibers 
in vivo, alignment of all the mature muscle fibers has to be observed to obtain a func-
tional construct. If muscle fibers contract in a uniform direction, optimal force will 
be delivered. Alignment can be maintained if the human muscle construct remains 
strained during maturation in vivo.
Alignment is also related to integration of the human muscle construct with the inner-
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vation. This will stimulate the human muscle construct, and promote alignment and 
contraction between muscle fibers. However, to reach functional innervation of a 
construct, two issues have to be addressed: first, the creation of a neuro-muscular 
junction, and second, the connection to the appropriate nuclei in the central nervous 
system. This will ultimately enable the patient to control movement of the integra-
ted muscle construct. The first innervation issue can be studied during integration 
of differentiating satellite cells and neural cells in a transgenic rat expressing green 
fluorescent protein in peripheral nerves [197]. This model offers new possibilities to 
visualize the integration of innervation and a muscle construct during development in 
the host. The second innervation issue will be solved through cross-face nerve grafts. 
This way, the neural signal will be transferred from the healthy facial nerve to the 
affected side of the face and the newly tissue engineered muscle constructs.
Subcutaneous implantation in nude rats offers a good model for tissue engineering 
with the purpose of reanimating human facial muscles. However, eventually tissue 
engineered muscle constructs have to be tested in larger animal models. In a pig 
model, host derived vascularisation, alignment and innervation will be very repre-
sentative for the human situation. Especially if facial paralysis is established first, this 
would be appropriate to study integration of a muscle construct, innervation and facial 
reanimation. Therefore, we can extrapolate the knowledge on well established rabbit 
models [198] in order to investigate facial reanimation after facial paralysis. 
Although several steps have to be made before tissue engineering of autologous ske-
letal muscle will be clinically applicable, the fundamental knowledge and tools we 
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Verlamming van het aangezicht is behalve een fysieke, ook een sociaal invaliderende 
aandoening. In een wereld waarin miljoenen besteed worden aan het uiterlijk, leidt 
een scheef gezicht bij een niet gering percentage van de patiënten tot ernstige psy-
chische stress en zelfs depressiviteit. Geschat wordt dat er jaarlijks zo’n 4.000 perso-
nen in Nederland een aangezichtsverlamming krijgen. Van deze patiënten, houden er 
zo’n 1.200 klachten en verschijnselen van de aangezichtsverlamming. Een groot deel 
van hen is met succes te behandelen. Er is een grote vooruitgang op het gebied van 
de reconstructieve chirurgie geboekt, en ook conservatieve bahandelstrategiën met 
bijvoorbeeld een mimetherapeut worden steeds verder ontwikkeld. Echter blijven er 
patiënten met deels onbehandelbare klachten zoals synkinesieën en spasmen, lagopht-
halmus en asymmetrie van het aangezicht. Voor deze groep patiënten moeten nieuwe, 
innovatieve behandelstrategieën ontwikkeld worden. Regenerative geneeskunde, en 
tissue engineering in het bijzonder, geeft een optie voor een potentiële nieuwe behan-
delstrategie.
Doel van dit proefschrift was om tissue engineering van de menselijke skeletspier te 
verbeteren door het aanbieden van nieuwe fundamentele inzichten en tools. 
Daarvoor hebben we in hoofdstuk 2 de stand van zaken op het gebied van tissue 
engineering van skelet spieren in kaart gebracht. Daaruit kwam naar voren dat een 
juiste voorloper cel en scaffold (dat is een soort steiger of kapstok) essentieel zijn in 
tissue engineering.  Wij vonden dat, uit verschillende voorloper cellen zoals beenmerg 
stamcellen, vet stamcellen en de muizen cellijn C2C12, menselijke satelliet cellen het 
meest geschikt zijn als bron voor tissue engineering van skeletspieren. Het gebruik 
van een 3D biologisch afbreekbare scaffold op basis van extracellulaire matrix, zoals 
fibrine of collageen, is geschikt om structurele steun te bieden aan cellen en bovendien 
de proliferatie en differentiatie van satelliet cellen te reguleren. Vervolgens is voor 
de overleving van getissue engineerde spieren een connectie met vasculaire stelsel 
vereist. Verschillende methoden om dit te bereiken zijn: 1) een vasculaire pedicle, 2) 
een geprevasculariseerde scaffold, 3) ingroei van de vaten vanuit de ontvanger, bij-
voorbeeld een methode waar lagen cellen gestapeld worden. Een andere voorwaarde 
voor het engineeren van functionele skeletspieren is een adequate verbinding met het 
zenuwstelsel. Dit kan bereikt worden door het toepassen van elektrische, chemotrofi-
sche of mechanische stimulatie tijdens engineering.
Echter, in het kader van engineering van autolog menselijk skeletspier, is er behoefte 
aan fundamentele kennis betreffende menselijke satelliet cellen. Daarvoor werd de 
differentiatie capaciteit van gekloonde menselijke satelliet cellen bestudeerd in hoofd-
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stuk 3. We zagen dat menselijke satelliet cellen tijdens differentiatie in vitro, hetzij 
myotubes, dat zijn onvolwassen spiervezels, hetzij nieuwe quiescent satelliet cellen 
vormen. Vervolgens bestudeerden we het reguleringsmechanisme tijdens de differen-
tiatie op post-transcriptioneel niveau. Ze zagen dat over het algemeen microRNA’s 
afnemen in quiescent satelliet cellen. Verder bevestigen we dat microRNA-1 en 
microRNA-206 sterk verhoogde zijn in myotubes.
De therapeutische toepassing van deze vindingen in tissue engineering is in hoofdtuk 
4 aan de orde. Omdat gedurende ons leven de regeneratieve capaciteiten van onze 
satelliet cellen achteruit gaat, is verbetering van differentiatie vooral voor oudere pati-
enten belangrijk. De microRNA’s die mede verantwoordelijk zijn voor het bevorderen 
van spiervezelformatie hebben we toegepast op satelliet cellen in een in vitro 3D 
model. Met deze methode worden spierconstructen gemaakt van humane satelliet cel-
len en collageen type I. Met de manipulatie van de satelliet cellen door microRNA’s 
kunnen we inderdaad de spiervezel formatie verbeteren.
Een andere belangrijke fundamentele kwestie is dat satelliet cellen op het moment van 
implantatie in een patiënt, in een zuurstofarm milieu terecht zullen komen. Hypoxie 
heeft een sterke invloed op de overleving, proliferatie en differentiatie van humane 
satelliet cellen. Daarom hebben we in hoofdstuk 5 onderzocht hoe satelliet cellen 
reageren op een lage zuurstof spanning, en wat er gebeurt op het moment dat satelliet 
cellen in een zuurstofarm milieu differentieren. We zagen dat humane satelliet cellen 
zeer goed bestand zijn tegen een lage zuurstofspanning. Ze worden kortstondig aan-
gespoord om te prolifereren, en verliezen bovendien niets van hun myogene capaci-
teiten. Dit maakt humane satelliet cellen zeer geschikt voor tissue engineering van de 
skeletspieren voor klinische toepassingen.
Tenslotte worden in hoofdstuk 6 de differentiatie en maturatie van gekloonde men-
selijke satelliet cellen onderzocht in een 3D collageen I spier construct dat subcutaan 
in naakt ratten is geïmplanteerd. Bovendien, met betrekking tot de in vivo vasculari-
satie, hebben we ook het effect onderzocht van in vitro preconditionering van deze 
spier constructen met humane navelstreng endotheelcellen (HUVEC). We zien dat 
gekloonde menselijke satelliet cellen volledig matureren in vivo en differentiëren 
in spiervezels en quiescent satelliet cellen. Deze gematureerde spiervezels werden 
goed gevasculariseerd door vaten van de naakte rat. Dit specifiek als gevolg van de 
humande satelliet cellen, te concluderen uit het feit dat de collageen type I gels zelf 
geen vascularisatie induceerden. De spiervezel maturatie en ook de vascularisatie 
weren beide niet veranderd door het preconditioneren met HUVEC.
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Kortom, de nieuwe inzichten en handvaten die we hebben besproken in dit proef-
schrift vormen een stevige basis voor tissue engineering van de menselijke skeletspier 
van menselijke satelliet cellen. We hebben aangetoond dat satelliet cellen en myotu-
bes in een collageen type I construct subcutaan differentiëren en matureren tot goed 
doorbloedde, volwassen spiervezels en quiescent satelliet cellen. Verder hebben we 
aangetoond dat gekloonde menselijke satelliet cellen gemoduleerd kunnen worden 
door microRNA’s. Dit biedt, vooral bij oudere patiënten, mogelijkheden om het engi-




Hoe vaak krijg je nou de kans om de mensen die je waardeert te kunnen bedanken ‘in 
print’? En kansen moet je grijpen, want ik ben jullie dankbaar, zonder jullie had ik dit 
proefschrift niet geschreven.
Mijn eerste promotor prof. dr. P.M.N. Werker. Beste Paul, jij hebt altijd the big picture 
voor ogen waardoor dit proefschrift de klinische inslag heeft gekregen die we vanaf 
de start voor ogen hadden. Dankbaar ben ik ook voor je vertrouwen en het geduld dat 
je hebt gehad. Dat zijn essentiële ingrediënten voor een beginnend onderzoeker. Ik 
kijk uit naar de volgende fase waarin je mijn opleider bent.
Mijn co-promotor, dr. M.C. Harmsen. Beste Marco, zonder jou had deze promotie niet 
de vorm gekregen die hij nu heeft. Met je bevlogenheid voor wetenschap weet je ook 
mij elke keer weer te enthousiasmeren. Dank voor alles wat je me geleerd hebt, van 
tevoren had ik dit niet gedacht. Jou wetenschaps-, onderwijs- en schrijfkunsten heb-
ben mij tot onderzoeker gevormd.
Mijn tweede promotor, prof. dr. M.J.A. van Luyn. Beste Marja, in de slotfase hebben 
we spijkers met koppen geslagen. Dank voor je betrokkenheid bij het onderzoek, met 
name hoofdstuk 6 is er prachtig door geworden. En door je betrokkenheid bij mij als 
persoon ben ik een beter mens geworden. Trots als een pauw!
Dr. D.W.J. van der Schaft, beste Daisy, wat een geluk dat wij elkaar in Davos tegen het 
lijf zijn gelopen. Het heeft tot hoofdstuk 4 én hoofdstuk 6 geleid, een geslaagd congres 
dus! Van jou toepassings gerichte kijk op tissue engineering heb ik veel geleerd.
Prof. dr. R.A. Bank, beste Ruud, dank voor je kortstondige begeleiding. Het is ontzet-
tend fijn dat je mij en mijn onderzoek hebt willen ‘adopteren’. Het heeft tot een mooi 
hoofdstuk 4 geleid en bij mij een interesse voor collageen en fibrose.
Natuurlijk wil in de leescommissie, Prof. dr. Berend van der Lei, Prof. dr. Mark H. 
Post en Prof. dr. Wout F.J. Feitz bedanken voor de uitvoer van de belangrijke taak om 
dit proefschrift te beoordelen.
Zonder collega’s op de werkvloer was het helemaal niets geworden, zo groen als 
gras begonnen aan dit project, nog nooit een pipet gezien. Maar jullie hebben mij 
wegwijsgemaakt, zowel praktisch als bij het interpreteren en uitwerken van data. De 
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ontelbare kopjes koffie dan wel biertjes met bijbehorende wetenschappelijke en vaak 
ook minder wetenschappelijke discussies hebben mij de afgelopen 4 jaar doorgehol-
pen. De AIO’s Jan-Reinier Moonen, Sander van Putten (mijn lunch- en koffie maatje, 
ik denk inderdaad dat mensen productiever zijn als ze lekker kunnen klagen :-)), Ee 
Soo Lee, Ewa Przybyt, Nynke Hospers, Diana Ploeger, Jurjen Zandstra, Rutger Gjal-
tema, Marloes de Groote, Christian Huisman, Mojtaba Parvizi, Monika Maleszewska, 
Gazele Hajmousa en Nina Schweinfurth. 
De analysten Josee Plantinga, Marja Brinker, Jasper Koerts, Peter Zwiers, Martin 
Schipper, Henk Moorlag, Anita Niemarkt, Linda Brouwer, Saskia de Rond, Inge 
Kazemier, Henriette Morselt, Jelleke Dokter, Henk Moes, Roelof-Jan van de Leij, 
Geert Mesander, Arjen Peters en Klaas Sjollema. Natuurlijk hoort Jochem Prop in 
dit dankwoord thuis die mij met zijn kennis en kunde door de Dec aanvragen heeft 
geloodst. De post-doc’s Guido Krenning (dank voor de vele broodkruimels), Eliane 
Popa, Marike van Beuge en Patricia Dankers. 
Ook studenten maken onmiskenbaar deel uit van het lab, en van hen begeleiden en 
onderwijzen heb ik veel geleerd, bedankt! Erik, dank voor de fanastische opmaat van 
al het werk dat volgde. Anne en Karlijn, voor jullie pionierwerk met de microRNA’s 
en Jacqueline voor de hulp met het in vivo werk.
Ik heb het geluk gehad in mijn promotietijd ook bij de afdeling plastische chirugie te 
horen, en alle daaruit voortvloeiende gezelligheid. Het jaarlijkse skitripje, congressen, 
borrels, zeilen en kopjes koffie/alcohol helpen om af en toe het lab uit te komen. De 
plastisch chirurgen Berend van der Lei, Yassir Eltahir, Tim Middelberg, Mike Rüt-
termann, Thomas Wermter, Dagna Lichtendahl, Lars Lahoda (fijn om de passie voor 
wetenschap en congressen te delen), Wiebren van de Berg, Martin Stenekes, en zeker 
Coralien Broekhuizen en Irene Krabbe (dank voor jullie inzet bij het vorm geven aan 
mijn opleidingsplek). 
De AIOS Jesse van Lieshout, Steven Klein, Steven Korteweg, Vick Sreetharan, Patrick 
Khoe, Marc Kioe-A-Sen, Marijn Huijing (de huizenjacht, vele biertjes met bitter-
ballen en het fietsen waren allemaal top!), Mireille Bolster, Ellen Meerman, Johan 
Wijbenga (fijn dat je nu al mijn collega bent) en Rinze Zwanenburg (op naar alle cur-
sussen die nog volgen). Ook Jacoline (altijd gezellig om even een praatje te maken), 
Elisabeth Sijbesma, Etty de Jong, Antoinette van Minnen en Bert Tebbes (fietsen en 
foto’s, daarover kunnen we eindeloos kletsen). En de plastisch chirurgen en artsen uit 
Leeuwarden wil ik bedanken voor de gezelligheid door de jaren heen, met name dr. 
J.J. van der Biezen, Eddie Verschuur en Marije Smittenberg voor het fietsen en skiën.
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De chirurgen en artsen uit het Martini Ziekenhuis, ik vind het heerlijk weer terug te 
zijn in de kliniek en met jullie de volgende uitdaging aan te gaan.
Mijn collega’s van het SWOAHS, dank dat ik de komende jaren nog mag genieten 
van jullie goede gezelschap, goed eten en natuurlijk de wetenschap.
In de loop der jaren hebben velen anderen mijn pad gekruist met koffie, drankjes, 
onderzoek en natuurlijk de daarbij gepaard gaande gesprekken, een paar wil ik bij 
naam noemen: Niels Harlaar, Wendeline van Eede, Anton Breeuwsma, Nico van 
Bakelen, Renske Dikkers, Evert-Jan ten Dam, Rosanne Lanting en Sophie Post.
Mijn vrienden Danielle en Barry met de kids, fijn dat julle mijn vrienden zijn. Jurrijn 
en Monique, Bart en Roelfien, al sinds onze tijd bij Volonté geniet ik van onze activi-
teiten samen, dat er nog maar veel mogen volgen.
Mijn jaarclub Blixem, wat heb ik een geluk dat ik jullie mijn vriendinnen mag noe-
men! Mooie tijden, alweer het 2e lustrum en nóg steeds vinden we elk jaar wel een 
mogelijkheid om samen op vakantie te gaan, op naar het 3e! Ik zou wensen dat Gro-
ningen niet zover was, maar des te meer geniet ik van de etentjes, feestjes, het winke-
len, fietsen en de weekendjes weg.
Corrie en Naud, Agniet en Koos, jullie aanwezigheid tijdens mijn jonge jaren hebben 
mij onmiskenbaar gevormd tot wie ik ben.
Mijn paranimfen Miriam en Guido, dolblij dat jullie hier naast mij staan. En ik ben 
ontzettend trots en vereerd ook jullie straks bij te mogen staan!
Lieve Miriam, mijn steun en toeverlaat, zowel op als buiten het lab. Je bent de meest 
gastvrije en mooie persoon die ik ken, ik maak altijd met veel plezier gebruik van de 
gezelligheid bij jou en Marten thuis. Onze zaterdagmiddagbiertjes zijn een essentieel 
ingredient om de week te bespreken en vol goede moed de nieuwe week het hoofd te 
kunnen bieden.
Beste Guido, mijn lot- en deelgenoot, de vele uurtjes op de golfbaan waren rust 
momenten die onontbeerlijk zijn tijdens onderzoek. Ook de etentjes en zeiltochtjes 




Benny en Cisca, het is fijn om zoveel warmte te krijgen in jullie gezin, ik ben blij 
dat ik er deel van uit mag maken. Jeffrey, mijn schoonbroer, ik denk dat jij het beste 
begreep wat ik deed, en hoe het eraan toe gaat. 
Hans en Wendy, Marc en Ellen, Martijn en Famke en natuurlijk alle kids, fijn dat jul-
lie deel uit maken van mijn familie, altijd goed om jullie te zien en spreken, met de 
kinderen te spelen of in de Porsche te cruisen.
Guido en Yvonne, Guido, ik ben ontzettend trots op jou en de manier waarop jij van 
het leven geniet, daar kan ik nog veel van leren. Yvonne, ik vind het heel fijn dat jij 
mijn schoonzusje bent.
Lieve mam en Henk. Mam, je bent mijn grote voorbeeld, de kracht waarmee jij in 
het leven staat vind ik bewonderingswaardig. De dagjes die we af en toe samen wat 
leuks doen zijn heel waardevol voor mij. Ook pap geniet vandaag met ons mee, hij is 
er altijd bij. Henk, fijn dat jij ons gezin weer compleet hebt gemaakt, ik heb het heel 
goed gehad in Apeldoorn. Ik floreer door jullie steun.
Lieve Kevin, je bent fantastisch! Jouw liefde, steun en begrip zijn essentieel voor mij, 
het is mijn drijvende kracht. Ik geniet met volle teugen van elke dag met jou, en ons 
leven samen.
